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ABSTRACT OF THE DISSERTATION 
ABSOLUTE CONFIGURATION AND BIOSYNTHESIS OF PAHAYOKOLIDE A 
FROM LYNGBYA SP. STRAIN 15-2 OF THE FLORIDA EVERGLADES 
by 
Li Liu 
Florida International University, 2009 
Miami, Florida 
Professor Kathleen S. Rein, Major Professor 
         Pahayokolides A-D are cytotoxic cyclic polypeptides produced by the freshwater 
cyanobacterium Lyngbya sp. strain 15-2 that possess an unusual -amino acid, 3-amino-
2,5,7,8-tetrahydroxy-10-methylundecanoic acid (Athmu). The absolute configuration of 
pahayokolides A-D was determined using advanced Marfey’s method. It was also 
confirmed that a pendant N-acetyl-N-methyl leucine moiety in pahayokolide A was 
absent in pahayokolides B and pahayokolides C-D were conformers of pahayokolide A. 
Feeding experiments indicated that the biosynthesis of the Athmu sidechain arises from 
leucine or α-ketoisovalerate, however could not be further extended by three rounds of 
condensation with malonate units. Putative four peptide and one unique polyketide 
synthetases in Lyngbya sp. strain 15-2 were identified by using a PCR method and 
degenerate primers derived from conserved core sequences of known NRPSs and PKSs. 
Identification of one unique KS domain conflicted with the logic rule that the long side 
chain of Athmu was assembled by three rounds of ketide extensions if PKSs were 
involved. A gene cluster (pah) encoding a peptide synthetase putatively producing 
pahayokolide was cloned, partially sequenced and characterized. Seven modules of the 
vi 
 
non-ribosomal peptide synthetase (NRPS) were identified. Ten additional opening 
reading frames (ORFs) were found, responsible for peptide resistance, transport and 
degradation. Although the predicted substrate specificities of NRPS agreed with the 
structure of pahayokolide A partially, the disagreement could be explained. However, no 
PKS gene was found in the pah gene cluster.  
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Scope of the dissertation 
 
         Lyngbya, a common and accessible genus of cyanobacteria, produce numerous and 
structurally diverse secondary metabolites, including nonribosomal peptides and 
polyketides in particular. Many novel structures have been elucidated as a result of 
systematic screenings for anticancer, antibacterial, antifungal, and protease inhibitory 
effects (Moore, et al, 1996; Namikoshi, et al, 1996). Some Lyngbya compounds prove 
potential for development into commercial drugs. However, few biosynthetic gene 
clusters of Lyngbya peptides have been characterized to date and their heterologous 
expression needs to be established. 
         Pahayokolides A-D are branched-cyclic peptides isolated from freshwater Lyngbya 
sp. strain 15-2 of the Florida Everglades. Revealing the absolute configuration of 
pahayokolide A is the basis for understanding its bioactivities. The study of pahayokolide 
A and their biosynthetic origins has great value not only for drug discovery but also for 
harnessing these pathways to create new molecules of pharmaceutical interesting 
(Gerwick, et al., 2001).  
         The specific aims of this study were to determine the absolute configuration of 
pahayokolides A-D (Chapter 1), identify the biosynthetic origin of the Athmu moiety in 
pahayokolide A (Chapter 2), and clone and characterize the genes coding for the 
biosynthesis of pahayokolide A in Lyngbya sp. strain 15-2. (Chapter 2)  
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1. Polypeptides Isolated from Lyngbya Species 
 
1.1 Introduction  
 
         Cyanobacteria, also called blue-green algae, are ancient aquatic and photosynthetic 
prokaryotes. The oldest known fossils cyanobacteria are from Archaean rocks of Western 
Australia, dated at 3.5 billion years (Stanley, 2004). Cyanobacteria share traits with both 
plants and bacteria. Like algae, cyanobacteria form oxygen during photosynthesis. Like 
other bacteria, cyanobacteria lack a nucleus and other internal organelles bound by 
membranes. However, there is an important difference between cyanobacteria and algae. 
Some cyanobacteria can fix nitrogen from the atmosphere. Therefore, they can become 
dominant over eukaryotic algae in nitrogen limited waters, because phosphorus and 
nitrogen are required for algal and cyanobacterial growth (Patočka, 2001). 
          A high degree of biological adaptation affords cyanobacteria the ability to produce 
a unique range of defensive secondary metabolites [Gerwick et al., 1994 and 2001; 
Namikoshi et al., 1996; Mayer et al., 2003]. Over 300 nitrogen-containing secondary 
metabolites from marine cyanobacteria have been reported in the literature (Tan, 2007).  
These secondary metabolites often enable cyanobacteria to compete effectively in a 
variety of environments and successfully inhabit extreme niches. Cyanobacterial 
secondary metabolites exhibit a variety of molecular structures and biological activities, 
especially those associated with inhibiting growth and development in other organisms. 
Cyanobacteria as a potential source for drug have generated scientific interest.  A number 
of cyanobacterial secondary metabolites have been discovered as potential lead 
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compounds for further drug development. One compound already in clinical trials for the 
treatment of cancer is based on the cryptophycins isolated from terrestrial cyanobacteria 
(Trimurtulu et al.; 1994). 
          Cyanobacterial secondary metabolites are often isolated by bioassay guided 
fractionation (BGF) using a variety of biological screening methods. The main purpose of 
the BGF strategy is to divide the fractions of a cyanobacterial extract into two classes: the 
amenable and discarded fractions. The amenable fractions show a reasonable expectation 
in the bioactivity test and will be separated, typically chromatographically, into several 
subfractions. The discarded fractions do not contain a discrete, identifiable component 
responsible for the observed activity and follow-up efforts are usually discontinued. 
Subfractions giving a positive response in the confirming bioassay will be followed up 
for purification of active components (Phillipson, et al., 2002). 
          Some cyanobacterial secondary metabolites were also isolated from marine 
invertebrates. The presence of a natural product within a particular cell type cannot 
provide unequivocal proof for the biosynthetic origin of a given compound. 
Conceptually, demonstrating the biosynthesis of a natural product in a given cell type can 
be achieved on chemical, protein, or genetic levels. 
          The wide occurrence of toxin producing cyanobacteria in freshwater and seawater 
creates problems for all life forms. Cyanobacterial toxins are often responsible for acute 
lethal, chronic and sub-chronic poisonings of wild and/or domestic animals and humans 
(Carmichael, 1994, 1997; Jochimsen et al., 1998; Falconer, 1999; Daranas et al., 2001). 
Cyanobacterial toxins may be classified by how they affect the human body (Patočka, 
2001). Hepatotoxins, are produced by some strains of the cyanobacteria Microcystis, 
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Anabaena, Oscillatoria, Nodularia, Nostoc, Cylindrospermopsis and Umezakia. 
Neurotoxins, produced by some strains of Aphanizomenon and Oscilatoria, affect the 
nervous system. Cylindroapermopsis raciborski may also produce toxic alkaloids, 
causing gastrointestinal symptoms or kidney disease in humans. Not all cyanobacteria 
form toxins, and it is likely that there are as yet many unrecognized toxins. 
           The taxonomy of cyanobacteria is complex and controversial (Patočka, 2001). 
Cyanobacteria of toxicological significance belong to the genus Anabaena, Oscillatoria, 
Microcystis, Nodularia, Cylindrospermopsis and Lyngbya. Lyngbya sp. and Microcystis 
sp. are easily collected and cultured in laboratory so that the isolation of compounds in 
mg range, while laborious and time consuming (Welker et al., 2006), is achievable. 
Lyngbya is a common and accessible genus of cyanobacteria, which is distributed 
worldwide throughout tropical and subtropical regions. The unbranched filaments of 
Lyngbya are cylindrical and usually wider than 6 µm. The straight, slightly wavy, or 
rarely coiled Lyngbya filaments usually form large, layered, leathery mats of varied 
thickness, and then form large benthic and surface blooms in freshwater and sea water. 
The most important species of genus Lyngbya are L. majuscule, L. martensiana, L. 
aestuarri and L. wollei. There are an increasing number of Lyngbya species which have 
been found to produce an impressive array of structurally varied compounds with diverse 
biological activities [Gerwick et al, 2001]. A major group of cyanobacterial secondary 
metabolites are peptides or contain peptide substructures. A total of 108 polypeptides 
isolated from Lyngbya species, published between January 2001 and October 2009, are 
reviewed with emphasis on their structural diversity and biological activities. The gross 
structures of these molecules were determined using 1D and 2D NMR spectroscopy. The 
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relative and/or absolute configurations were elucidated by chemical manipulation 
including the advanced Marfey’s method, successful application of the J-based 
configuration analysis, Mosher analysis, and organic synthesis of the stereoisomers (Tan, 
2007). 
 
H
N
H
Cl R
OO
N O
O
 
Jamaicamide A (1) R=Br, Jamaicamide B (2) R=H 
 
H
N
H
Cl
OO
N O
O
  
Jamaicamide C (3) 
1.1.1 Acyclic polypeptides 
           A screening program for bioactive compounds from marine cyanobacteria led to 
the isolation of jamaicamides A-C from a dark green strain of Lyngbya majuscule found 
in Hector’s Bay, Jamaica (Edwards et al., 2004). Jamaicamides A-C (1-3) are highly 
functionalized lipopeptides containing a terminal alkynyl or alkene, vinyl chloride, β-
methoxy enone system, and pyrrolinone ring. Jamaicamides A-C (1-3) exhibited 
cytotoxicity (LC50 = 15 µM) to both the H-460 human lung and Neuro-2a mouse 
neurocamide cell lines, sodium channel blocking activity and goldfish toxicity. 
Jamaicamide B (2) was the most active fish toxin and followed by jamaicamide C (3). 
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Interestingly, the nonaromatic ring-containing alkynoic lipopeptide jamaicamide B (2) 
showed weak antimalarial activity (IC50 = 18.4 µM). However, the terminal 
bromoacetylene homologue jamaicamide A was inactive in this assay (IC50 > 50 µM). 
          Three polychlorinated metabolites, pseudodysidenin (5), nordysidenin (6), and 
dysidenamide (7) were identified from a marine free-living red cyanobacterium, Lyngbya 
majuscule, collected at Boca del Drago Beach, Bocas del Toro, Panama (Jiménez et al., 
2001). Compounds 5-7 are closely related to dysidenin (4) and isodysidenin (8) isolated 
from Australian and New Guinean specimens of Dysidea herbacea, respectively. This is 
the first report strengthening that sponge-based dysidenins are biosynthesized by 
associated cyanobacteria. The relative and absolute configurations of compounds 5-7 
were established by chiral HPLC and optical rotation comparison to other chlorine-
containing metabolites. Pseudodysidenin (5) exhibits cytotoxicity against four neoplastic 
cell lines P-388, A-549, HT-29, and MEL-28 (IC50 > 1 μg/mL). 
 
N CCl3
O
R1
Cl3C
NO
N
S
R2
N CCl3
O
H
Cl3C
NO
O
NH2
Me
N CCl3
O
H
Cl3C
NO
N
S
Me
 
Dysidenin (4)   R1=CH3, R2=H 
CH3            Dysidenamide (7)                              Isodysidenin (8) 
           The apratoxin-producing Lyngbya sp. NIH309 from Palau also afforded several 
other nitrogenous metabolites, including palau’imide (10) (Luesch et al., 2002b). 
Pseudodysidenin (5) R1=H, R2=
Nordysidenin (6) R1=H, R2=H 
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Palau’imide was unique and structurally unrelated to any other compounds isolated from 
the organism from Guam. The N-acylpyrrolinone unit in palau’imide (10) has precedence 
in dysidin (9) from the sponge Dysidea herbacea, albeit most likely produced by a 
symbiotic cyanobacterium (Hofheinz, et al., 1977). Palau’imide exhibited IC50 values of 
1.4 and 0.36 mM for in vitro cytotoxicity against KB and LoVo cells, respectively. 
 
NCl3C
O CCl3
O NH
N
S
N
H
O
O
N
O
O
 
Dysidin (9)                                                           Palau'imide (10) 
 
           Six structurally-related linear lipopeptides, including dragonamide A (11) 
(Jiménez et al., 2001), carmabin A (13), dragomabin (14) and dragonamide B (12) 
(Mcphail et. al., 2007), dragonamide C (15) and D (16) (Gunasekera et al., 2008a) were 
isolated from the marine cyanobacteria Lyngbya majuscule and Lyngbya polychroa. A 
unique C8-alkynoate unit has been found in carmabin A, dragomabin, dragonamides A 
and B. Dragonamide A (11) exhibits cytotoxicity against four neoplastic cell lines P-388, 
A-549, HT-29, and MEL-28 (IC50 > 1 μg/mL). To the best of our knowledge, carmabin A 
(13), dragomabin (14), and dragonamide A (11) were the only Lyngbya metabolites 
showing good antimalarial activity (IC50 = 4.3, 6.0, and 7.7 μM, respectively), whereas 
the nonaromatic analogue, dragonamide B (12), was inactive. The lack of activity for 
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dragonamide B (12) suggests that an aromatic amino acid at the carboxy terminus is 
necessary for antimalarial activity in this compound series. Carmabin A (13) was more 
 
Acyl
N
N
N
N
NH2
O
O
O
O
R4
R1 R3
R2  
 
Name R1 R2 R3 R4 Acyl 
Dragonamide A (11) i-Pr i-Pr i-Pr 4-(MeO)PhCH2- 
 
Dragonamide B (12) i-Pr i-Pr i-Pr i-Pr 
 
Dragonamide C (15) i-Pr i-Pr i-Pr i-Pr 
 
Dragonamide D (16) i-Pr i-Pr i-Pr i-Pr 
 
Carmabin A (13) Bn Me Me 4-(MeO)PhCH2- 
 
Dragomabin A (14) Me Bn Me Me 
 
 
cytotoxic to Vero cells (IC50 = 9.8 µM) than dragomabin (IC50 = 182.3 µM) or 
dragonamide A (IC50 = 67.8 µM), and thus, dragomabin possesses the best differential 
toxicity between parasite and mammalian cells. The Vero cell line is derived from kidney 
epithelial cells of the African Green Monkey. It appears that the presence of three extra 
carbons in the aliphatic chain leads to the increase in cytotoxicity of carmabin A (13) 
over that of dragomabin. Dragonamides C (15) and D (16) showed weak activity in 
cancer cell viability assays, with GI50 values of 56 and 59 µM against U2OS 
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osteosarcoma cells, 22 and 32 µM against HT29 colon adenocarcinoma cells, and 49 and 
51 µM against IMR-32 neuroblastoma cells, respectively. These data are similar to 
cytotoxicity data reported for dragonamides A (11) and B (12) against other cell lines. 
           Several collections of Lyngbya sp. VP417, from Finger’s Reef, Apra Harbor, 
Guam and Lyngbya sp. NIH309 from Palau have yielded three more members of the 
lyngbyapeptin family, termed 15-norlyngbyapeptin A (17) (Williams et al., 2003c), 
lyngbyapeptins B and C (19-20) (Luesch et al., 2002b). In comparison to lyngbyapeptin 
A (18), the peptides 19 and 20 possess the same (for 19) or similar (for 20) characteristic 
C and N-terminal modification and differ by containing other amino acid units in 
between. Like lyngbyapeptin A (18), compounds 19 and 20 were noncytotoxic against 
KB and LoVo cells at <5 mM.  
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15-Norlyngbyapeptin A (17) R=H                                       Lyngbyapepetin B (19) R=Me 
Lyngbyapepetin A (18) R=Me                                             Lyngbyapepetin C (20) R=Et 
 
Three acyclic members of the lyngbyabellin family, D (21) (Williams et al., 
2003c), F (22) and I (23) (Han et al., 2005) have been isolated from Lyngbya sp. VP417 
collected from Finger’s Reef, Apra Harbor, Guam and L. majuscule collected in Hector 
Bay, Jamaica and Alotau Bay, Papua New Guinea, respectively. Structurally, 
lyngbyabellins D (21), F and I resemble dolabellin (24) isolated from the Japanese sea 
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hare Dolabella auricularia (Sone et al., 1995). Lyngbyabellin D (21), containing a rare γ-
amino-β-hydroxy acid, is the largest member of the lyngbyabellin family. There is no 
general method for determining the configuration of the chiral centers in γ-amino-β-
hydroxy acids. However, Rinehart reported that 4-amino-3-hydroxy-5-methylheptanoic 
acid underwent an epimerization at C-3 via an acid-catalyzed dehydration/hydration 
sequence, and that significant quantities of the intermediate α, β-unsaturated acid existed 
after prolonged hydrolysis (Rinehart et al., 1992). The absolute configuration of C-29 
could be determined by acid hydrolysis and subsequent ozonolysis, with oxidative 
workup, to D- or L-valine. Chiral HPLC showed unambiguously that C-29 was derived 
from L-valine. H-28 and H-29 exhibited an 8.4 Hz  
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Lyngbyabellin D (21)                                  Lyngbyabellin F (22) R1=OH                Dolabellin (24) 
Lyngbyabellin I (23) R1=H 
 
coupling, enabling the relative configuration to be determined by a NOE experiment. 
Thus the stereochemistry of C-28 and C-29 in lyngbyabellin D (21) was assigned as 28S, 
29S. Because of limited amounts of lyngbyabellin I (23), the absolute stereochemistry 
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was not established by chemical methods, however, it was proposed to belong to the 
same enantiomeric series as lyngbyabellin F (22). Lyngbyabellin D (21) displayed an 
IC50 value of 0.1 μM against the KB cell line. Lyngbyabellin F and I were cytotoxicity to 
NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells and had LC50 
values between 0.7 and 1.8 mM. 
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Bisebromoamide (25) 
 
          The efforts toward finding novel marine cyanobacterial metabolites with antitumor 
activity led to the isolation of bisebromoamide from a Lyngbya sp. harvested in Okinawa 
Prefecture (Teruya et al., 2009). Bisebromoamide (25) possesses a dense combination of 
unusual structural features, including a 2-substituted thiazoline-4-methyl-4-carboxylic 
acid unit fused to a methyl-proline. Another unusual structural element is the 2-(1-
oxopropyl) pyrrolidine (Opp) residue and N-methyl-bromine-tyrosine. The Opp unit in 
bisebromoamide (25) is unprecedented in natural products. In addition, bisebromoamide 
(25) possesses an N-pivalamide moiety. Bisebromoamide (25) exhibited cytotoxicity 
against HeLa S3 cells with an IC50 value of 0.04 μg/mL, and the average 50% growth 
inhibition (GI50) value against a panel of 39 human cancer cell lines (termed JFCR39) at 
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40 nM. In addition, bisebromoamide (25) exhibited potent protein kinase inhibition: the 
phosphorylation of ERK (extracellular signal regulated protein kinase) in NRK cells by 
PDGF (platelet-derived growth factor)-stimulation was selectively inhibited by treatment 
with 10 to 0.1 μM of bisebromoamide (25).  
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Grassystatin C (28) 
 
          Three statin unite-containing linear peptides, termed grassystatins A-C (26-28), 
have been isolated from the marine cyanobacteria Lyngbya confervoides collected off 
Grassy Key (Kwan et al., 2009). Grassystatins A and B (26-27) showed similar potency 
and selectivity against cathepsins D (IC50s of 26.5 nM and 7.27 nM, respectively) and E 
(IC50s of 886 pM and 354 pM, respectively). The increased affinity for cathepsin E over 
cathepsin D may be interpreted by the interaction of the polar residue asparagine in 
grassystatins A and B (26-27) with glutamine-303 in cathepsin E, which replaces the 
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nonpolar residue methionine-307 in cathepsin D. Grassystatin A was observed to reduce 
antigen presentation by dendritic cells, a process thought to rely on cathepsin E. The 
truncated peptide analogue grassystatin C (28), which consists of two fewer residues than  
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Hectochlorin (29)                                                   Lyngbyabellin E (31) R=OH 
                                                                             Lyngbyabellin H (33) R=H 
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Lyngbyabellin C (30) R=Me                                   Lyngbyabellin A (34) R=Me 
Lyngbyabellin G (32) R=H                                     Lyngbyabellin B (35) R=H 
 
rassystatins A and B (26-27), was less potent against both cathepsins D and E, but still 
 
g
selective for cathepsin E. The selectivity of grassystatins A-C (26-28) for cathepsin E 
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over D (20-38-fold) suggests that these natural products may be useful tools to probe 
cathepsin E function.  
 
1.1.2 Cyclic polypeptides  
          Hectochlorin (29) (Marquez et al., 2002), lyngbyabellins C (30) (Luesch et al., 
2002b), E (31), G-H (32-33) (Han et al., 2005) have been reported from Lyngbya. 
Structurally, these five cyclic compounds resemble lyngbyabellins A (34) (Luesch et al., 
2000a) and B (35) (Luesch et al., 2000b). Hectochlorin possesses the same absolute 
configuration as dolabellin and lyngyabellins E, G and H except at the C14. Hectochlorin 
has potent antifungal activity against Candida albicans and antiproliferative activity in 
the NCI 60-cell line assay. The NCI 60-cell line assay utilized 60 different human tumor 
cell lines, representing leukemia, melanoma and cancers of the lung, colon, brain, ovary, 
breast, prostate, and kidney. Hectochlorin had an average GI50 against the NCI 60 cell 
lines of 5.1 μM and showed greatest potency against the colon, melanoma, ovarian, and 
renal panels. The IC50 values for in vitro cytotoxicity for lyngbyabellin C were 2.2 mM 
against KB and 3.3 mM against LoVo cells. The lyngbyabellins E-I were tested for 
cytotoxicity to NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells 
and had LC50 values between 0.2 and 4.8 mM. Intriguingly, lyngbyabellin E (31) and H 
(33) appeared to be more active against the H460 cell line with LC50 values of 0.4 and 0.2 
mM, respectively, compared to LC50 values of 1.2 and 1.4 mM in the neuro-2a cell line. 
Lynbyabellin I (23) was the most toxic to neuro-2a cells (LC50 = 0.7 mM), whereas 
lyngbyabellin G (32), was the least cytotoxic of all compounds to either cell line. On the 
basis of this limited screening, it appears that lung tumor cell toxicity is enhanced in the 
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cyclic representatives with an elaborated side chain. However, the fact that the acyclic 
compounds (lyngbyabellin F and I and dolabellin) are still relatively potent cytotoxins 
suggests two possibilities. One explanation is that the acyclic compounds may adopt a 
conformation similar to the cyclic forms at their target.  It is also possible that the acyclic 
forms are produced in vitro by intracellular esterases and represent the truly bioactive 
forms of these molecules. If this latter hypothesis is correct, then differences in potency 
between the cyclic and acyclic forms could be the result of differences in their 
permeability to cells. Unfortunately, the results are difficult to compare with those 
obtained for lyngbyabellins A–D, dolabellin, and a few other analogs produced 
synthetically or semi-synthetically because different cell lines were used (e.g., much of 
the present work is reported using the KB cell line, which is considerably more drug 
sensitive than the H-460 and neuro-2a cell lines). However, the trend in the data supports 
the conclusion drawn above that an overall cyclic constitution is not required for potent 
cytotoxic properties in this drug class. Lyngbyabellin E (31) was also tested for the 
cytoskeletal-disrupting activity because lyngbyabellin A and hectochlorin have been 
reported to be strong actin-disrupting agents (Luesch et al., 2000a; Marquez et al., 2002). 
Lyngbyabellin E (31), at concentrations of 0.01–6.0 mM, disrupted the cellular 
microfilament network in A-10 cells. Additionally, at the higher concentrations tested, 
many cells contained two nuclei, consistent with the inhibition of cytokinesis that often 
occurs after disruption of the microfilament network. The effects were specific for 
microfilaments, as there was no evidence of microtubule loss at these concentrations. 
          Antillatoxin B (36) was isolated from two Lyngbya majuscule collections from 
Collado Reef, Puerto Rico, and Bush Key, Dry Tortugas (Nogle et al., 2001a). Its 
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structure was deduced from 2D NMR and data comparisons with antillatoxin (37). 
Antillatoxin B contains an unusual N-methyl homophenylalanine which was only shown 
in a few cyanobacterial metabolites. Both antillatoxin (37) and antillatoxin B (36) are 
potent activators of the voltage-sensitive sodium channel in mouse neuro-2a 
neuroblastoma cells with EC50 values of 0.18 and 1.77 μM, respectively. In addition, 
antillatoxin B (36) is strongly ichthyotoxic to goldfish, with an LC50 of 1.0 μM. However, 
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Antillatoxin B (36)                                                          Antillatoxin (37) 
 
antillatoxin (37) is more toxic to goldfish than antillatoxin B (36), with a LC50 value at 
0.1 μM. It is interesting to note that in both measures of the biological activity of 
antillatoxin B’s (36), a 10-fold decrease in potency is observed compared to antillatoxin 
(37). It seems likely that substitution of a larger N-methyl homophenylalanine residue for 
an N-methyl valine residue accounts for this decrease.  
         Obyanamide (38) was isolated from the marine cyanobacterium Lyngbya 
confervoides collected in Saipan, Commonwealth of the Northern Mariana Islands 
(Williams et al., 2002). Obyanamide (38) is a novel depsipeptide containing 2 N-methyl 
amino acids, an Ala-thiazole unit, and a β-amino acid. The absolute stereochemistry of 
(38) was deduced by chiral chromatography of the hydrolysis products and comparison of 
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the retention time with authentic and synthetic standards. Obyanamide (38) was cytotoxic 
against KB and LoVo cells with an IC50 of 0.58 and 3.14µg/mL, respectively. 
           Six β-amino acid-containing cyclic depsipeptides, termed ulongamides A-F (39-
44), were isolated from collections of apratoxin-producing Lyngbya sp. NIH309 from  
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Obyanamide (38)                                              Ulongamide A (39) R1=i-Pr, R2=H 
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Palau (Luesch et al., 2002a). The stereochemistry of the β-amino acid moiety, 3-amino-2-
methylhexanoic acid, was established by advanced Marfey analysis of the acid 
hydrolyzates and found to be 2R, 3R in compounds 39-41 but 2S, 3R in compounds 42-
44. In comparison to obyanamide (38), which bears a 3-aminopentanoic acid moiety, 
compounds 39-44 contain a different β-amino acid unit. Remarkably, ulongamide A (39) 
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differs from obyanamide otherwise merely in the residue sequence, with the N-methyl-
valine and the N-methyl-phenylalanine residues being switched. The great structural 
variety of the ulongamides is intriguing and might suggest that enzymes with relaxed 
substrate specificity are involved in their biosynthesis or that slight genetic divergence 
among individual patches of this cyanobacterium might be responsible for the diversity. 
All compounds except 44 were weakly cytotoxic against KB cells. It suggests that the 
lack of an aromatic amino acid or the N-methyl group adjacent to the hydroxyl acid is 
detrimental to activity. 
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Apratoxins A (45) R1=Me, R2=Me 
Apratoxins B (46) R1=H,    R2=Me                                                  E-dehydroapratoxin A (48) 
Apratoxins C (47) R1=Me, R2=H 
 
          Two collections of Lyngbya sp. from Guam and Palau that both afforded the potent 
cytotoxin apratoxin A (45) (Luesch et al., 2001a) yielded different apratoxins analogues, 
apratoxins B (46) and C (47) (Luesch et al., 2002c). Apratoxins A-C (45-47) are 
presumably of mixed peptide-polyketide biogenesis. Apratoxin A (45) possesses IC50 
values for in vitro cytotoxicity against human tumor cell lines ranging from 0.36 to 0.52 
nM. It was only marginally active in vivo against a colon tumor and ineffective against a 
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mammary tumor. However, its potential as an antitumor agent was limited by the lack of 
selectivity.  Apratoxins B (46) and C (47), were evaluated for their in vitro cytotoxicity 
along with semisynthetic E-dehydroapratoxin A (48) to identify key structural elements 
responsible for the cytotoxicity of this novel family of depsipeptides. All analogues 46-48 
displayed weaker cytotoxicity than 45, but to different extents. The in vitro cytotoxicity 
of apratoxin C (47) almost approached that of apratoxin A (45), indicating that the tert-
butyl group is not essential for activity and can be replaced at least by the sterically less 
demanding isopropyl group. Apratoxin B (46) and especially E-dehydroapratoxin A (48)  
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Apratoxins D (49)                                                                        Apratoxins E (50) 
 
were significantly less cytotoxic than apratoxin A (45) and apratoxin C (47). Cytotoxicity 
decresing of (46) and (48) suggested that the N-methyl group of the Ile residue might 
play a role in the cytotoxicity as well as the 1,2-methine system (C34–C35) bearing the 
hydroxyl group. The NMR data also revealed a conformational change for compounds 2 
and 4 in CDCl3. Molecular modeling studies for apratoxin A (45) in CDCl3 demonstrated 
the spatial proximity of the N-methyl group of Ile and the hydroxyl group of the Dtena 
(3,7-dihydroxy-2,5,8,8-tetramethylnonanoic acid) unit. Perhaps this conformational 
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behavior is important under aqueous assay conditions and contributes to the observed 
activity loss as well. 
          Apratoxin D was isolated from the Papua New Guinea marine cyanobacteria 
Lyngbya majuscule and Lyngbya sordida (Gutiérrez et al., 2008). Apratoxin D (49) 
contains the same macrocycle as apratoxins A (45) and C (47) but possesses the novel 
3,7-dihydroxy-2,5,8,10,10-pentamethylundecanoic acid as the polyketide moiety. 
Apratoxin D (49) showed potent in vitro cytotoxicity against H-460 human lung cancer 
cells with an IC50 value of 2.6 nM, which is nearly equipotent to that of apratoxin A (45). 
The similar cytotoxicity of apratoxin A (45) and Apratoxin D (49) indicates that the 
cytotoxicity of apratoxins is not strongly impacted by the larger lipopeptide tail. This 
relationship could be important to the design of analogue structures for probing the 
mechanism of action of the apratoxins. The isolation of apratoxin D from two distinct 
species of the genus Lyngbya supports the hypothesis that genetic transfer of natural 
product biosynthetic pathways between different marine cyanobacteria is common 
(Simmons et al., 2008). 
          A collection of the marine cyanobacterium Lyngbya bouillonii from Guam afforded 
apratoxin E (50), an apratoxin cytotoxin (Matthew et al., 2008b). Apratoxin E (50) 
displayed strong cytotoxicity against several cancer cell lines derived from colon, cervix, 
and bone, ranging from 21 to 72 nM, which is lower than its closest analogues, E-
dehyroaparotoxin (48), yet 5-to 15-fold less active than apratoxin A (45). It suggests that 
the α,β-unsaturation of the modified cysteine residue is not essential for apratoxin 
activity. The 5- to 15-fold reduced activity of apratoxin E (50) compared with apratoxin 
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A (45) is attributed to the dehydration in the long-chain polyketide unit, which could 
affect the conformation of the molecule. 
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Guineamide A (51)                                  Guineamide B (52)                          Guineamide C (53) 
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Guineamide D (54)                                  Guineamide E (55)                         Guineamide F (56) 
 
          Guineamides A-F (51-56) are novel cyclic depsipeptides isolated and characterized 
from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscule 
(Tan et al., 2003). All six possessed N-methylated amino acids and β-amino acids, or β-
hydroxyl groups. The β-amino and β-hydroxyl residues are an increasingly common 
feature in marine cyanobacterial metabolites. The three β-amino acid residues present in 
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the guineamides [Mapa (2-methyl-3-aminobutanoic acid) in 51, Maba (2-methyl-3-
aminobutanoic acid) in 52, and Maoya (2-methyl-3-amino-oct-7-ynoic acid) in 53] are 
also present as constituents in molluscan metabolites (e.g., dolastatins D, 11, and 12 and 
onchidin A). It was speculated that these substances are originated from the 
cyanobacterial diet of the mollusc. Dmhha (2,2-dimethyl-3-hydroxyhexanoic acid) in 
guineamides E (55) and F (56) was reported for the first time. Guineamides B (52) and C 
(53) possess moderate cytotoxicity to a mouse neuroblastoma cell line with IC50 values of 
15 and 16 μM, respectively. 
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Antanapeptin A (57)  
R1=CH2CH2CH2C≡CH, R2=CH3 
 
Antanapeptin B (58)  
R1=CH2CH2CH2CH=CH2, R2=CH3 
 
Antanapeptin C (59)  
R1=CH2CH2CH2CH2CH3, R2=CH3 
 
Antanapeptin D (60)  
R1=CH2CH2C≡CH, R2=H 
 
          A series of depsipeptides, antanapeptins A-D (57-60) were isolated from a Lyngbya 
majuscule collection from Antany Mora, Madagascar (Nogle et al., 2002). The 
antanapeptins did not exhibit activity in several biological assays. Similarly, the related 
metabolite georgamide, isolated from an Australian cyanobacterial collection, did not 
possess biological properties (Wan et al., 2001). However, two other related metabolites, 
yanucamides A and B from a Fijian collection of L. majuscule, showed potent brine 
shrimp toxicity (Sitachitta et al., 2000). Thus, a specific biological function for this 
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structural class of compounds remains uncertain.  
          Trungapeptins A-C (61-63) were isolated from the marine cyanobacterium 
Lyngbya majuscule collected from Trung Province, Thailand (Bunyajetpong, et al., 
2006). The structures of compounds 61-63 are closely related to the antanapeptins, a 
series of depsipeptides isolated from a Madagascan collection of L. majuscule. The 
structures of compounds 61-63 contain the unique 3-hydroxy-2-methyl-7-octynoic acid 
(Hmoya), 3-hydroxy-2-methyl-7-octenoic acid (Hmoea), and 3-hydroxy-2-methyl-7-
octanoic acid (Hmoaa) residues, respectively. The relative stereochemistry of 3-hydroxy-
2-methyl-7-octynoic acid (Hmoya) of trungapeptin A was elucidated by application of 
the J-based configuration analysis (Matsumori et al., 1999). Its absolute stereochemistry  
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Huntupeptin A (64) 
 
was established to be 2S, 3R by Mosher’s method.  Trungapeptin A (61) showed mild 
brine shrimp toxicity at 10 ppm and mild ichthyotoxicity at 6.25 ppm but did not exhibit 
cytotoxicity against KB and LoVo cells at 10μg/mL. Due to a limited supply of 
compounds 62 and 63, their biological activities were not evaluated. 
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          The marine Lyngbya majuscule from Pulau Hantu Besar, Singapore afforded a 
cyclodepsipeptide, hantupeptin A (Tripathi et al, 2009). Hantupeptin A (64) showed 
100% brine shrimp toxicity at 100 and 10 ppm, which was significantly higher than the 
activity reported for its close analogue trungapeptin A (61), which exhibited mild brine  
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Aurilide (67)                                                                        Palau'amide (68) 
 
shrimp toxicity. Furthermore, in vitro cytotoxicity testing of 64 against the leukemia cell 
line MOLT-4 with an IC50 value of 32 nM. Compound 64 also displayed significant 
cytotoxicity in the breast cancer cell line MCF-7 with an IC50 value of 4.0 μM. In 
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comparison, trungapeptin A (61), was reported to be inactive when tested at 10 μg/mL 
against KB or LoVo cells. 
          Aurilides B (65) and C (66) were isolated from a strain of the marine 
cyanobacterium Lyngbya majuscule collected from Alotau Bay, Papua New Guinea (Han 
et al., 2006). Aurilides B and C are closely related to aurilide (67), originally isolated 
from the sea hare Dolabella auricularia. The isolation of aurilides B (65) and C (66) 
from the marine cyanobacterium L. majuscule clearly indicates that the sea hare D. 
auricularia obtains and accumulates aurilide (67) from its diet of marine cyanobacteria. 
Both aurilides B and C showed in vitro cytotoxicity toward NCI-H460 human lung tumor 
and the neuro-2a mouse neuroblastoma cell lines, with LC50 values between 0.01 and 
0.13 μM. Aurilide B (65) was evaluated in the NCI 60 cell line panel and exhibited a high 
level of cytotoxicity (the mean panel GI50 concentration was less than 10 nM) and to be 
particularly active against leukemia, renal and prostate cancer cell lines. 
          A species of Lyngbya from Ulong Channel in Palau has yielded palau’amide (68), 
which displayed strong cytotoxicity against KB cells with an IC50 value of 13 nM 
(Williams et al., 2003b). 
          Ulongapeptin (69), a cyclic depsipeptide, was isolated from a Palauan marine 
cyanobacterium Lyngbya sp. (Williams et al., 2003d). The absolute and relative 
stereochemistry of the β-amino acid, 3-amino-2-methyl-7-octynoic acid (AMO) in 69 
was determined by synthesis of the saturated α-alkyl-β-amino acid and Marfey’s analysis 
of the acid hydrolysate of tetrahydro-69. Two of the four valine units in ulongapeptin 
(69) are N-methylated, a percentage that mirrors that found in the literature. The presence 
of two D-configuration amino acids is unusual though since over 90% of the amino acids 
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incorporated into cyanobacterial metabolites have an L configuration. The AMO unit 
found in 69 has been previously identified in the molluskan metabolite onchidin 
(Fernandez-Suarez et al., 1997). Such β-amino acid units appear to be ubiquitous to 
cyanobacterial metabolites, and their appearance in compounds isolated from other 
marine organisms has often been suggested a dietary or symbiotic relationship between 
the two organisms. Ulongapeptin (69) was cytotoxic against KB cells at an IC50 value of 
0.63 μM. 
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       Ulongapeptin (69)                                          Pitipeptolide A (70) R= CH2C≡CH 
                                                                                   Pitipeptolide B (71) R= CH2CH=CH2 
 
          Two cyclodepsipeptides, pitipeptolides A (70) and B (71), have been isolated from 
the marine Lyngbya majuscule collected at Piti Bomb Holes, Guam (Luesch et al., 
2001b). The most distinctive features of pitipeptolides A (70) and B (71), the 2,2-
dimethyl-3-hydroxy-7-octynoic acid (Dhoya) and 2,2-dimethyl-3-hydroxy-7-octenoic 
acid (Dhoea) units, are found in some other marine natural products such as the kulolides, 
isolated from marine mollusks known for accumulating cyanobacterial metabolites via 
their diet, and yanucamides A and B (Dhoya), directly obtained from a cyanobacterial 
source. The isolation of compounds 70 and 71 provides more evidence that Dhoya and 
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Dhoea units are diagnostic for metabolites of cyanobacterial origin and that they can be 
considered biosynthetic signatures. Pitipeptolides A (70) and B (71) exhibit weak 
cytotoxicity against LoVo cancer cells, but possess moderate antimycrobacterial activity 
and stimulate elastase activity. 
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Grassypeptolide (72)                                                               Lissoclinamide 7 (73) 
 
          A collection of the cyanobacterium Lyngbya confervoides from the Florida Keys 
yielded grassypeptolide (72), a macrocyclic depsipeptide with unusually high D-amino 
acid content, two thiazolines, and one β-amino acid (Kwan et al., 2008). Grassypeptolide 
(72) inhibited four cancer cell lines derived from human osteosarcoma (U2OS), cervical 
carcinoma (HeLa), colorectal adenocarcinoma (HT29), and neuroblastoma (IMR-32) 
with IC50 values from 1.0 to 4.2 µM. These data are within the range of IC50 values 
reported for lissoclinamide 7 (73) (53.7 nM to 21.5 µM), but in different cell lines 
(Hawkins et al., 1990; Wipf et al., 1998). Lissoclinamide 7 (73), the most cytotoxic of the 
lissoclinamide series, has two thiazoline rings with the same arrangement and 
stereoconfiguration as 72. It has been shown that the thiazolines of 73 are important to its 
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cytotoxic activity (Wipf et al., 1998). It is tempting to speculate that the thiazolines might 
also be responsible for the activity of 72, and that it might indicate a shared mechanism 
of action with the lissoclinamides (73). 
          A cyclodepsipeptide, termed carriebowmide (74) was isolated from Lyngbya 
polychroa collected from Carrie Bow Cay, Belize (Gunasekera et al., 2008b). 
Carriebowmide (74) contains two rare amino acids, 3-amino-2-methylhexanoic acid and 
methionine sulfoxide. 
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                 Dolastatin 16 (75)                                                                        Homodolastatin 16 (76) 
 
          The known dolastatin 16 (75) was isolated from a Lyngbya majuscule collection 
from Antany Mora, Madagascar (Nogle et al., 2002). The isolation of dolastatins 3, 10, 
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12, and 16 from various microalgal collections demonstrate their origin in cyanobacteria. 
In addition to a known cyclic depsipeptide antanapeptin A (57), a bioactive cyclic 
depsipeptide, homodolastatin 16 (76) has been isolated from the cyanobacterium Lyngbya 
majuscule, collected from Wasini Island off the southern Kenyan coast (Davies-Coleman 
et al., 2003). The stereochemistry of the 3-hydroxy-2-methyl-7-octynoic acid (Hmoya) in 
57 and the dolaphenvaline (Dpv) and dolamethylleucine (Dml) fragments in 76 remains 
unassigned. The L-configuration of the lactate residue in dolastatin 16 (75) was originally 
established from chiral HPLC data. However, several attempts, using both chiral GC 
analysis and HPLC (with precolumn derivatization), failed to reproducibly establish the 
stereochemistry of the lactate residue in homodolastatin 16 (76). In spite of the strong 
activity of dolastatin 16 (75) against a wide variety of cancer cell lines, e.g., lung (NCI-
H460: GI50=0.00096 μg/mL), colon (KM20L2 GI50= 0.0012 μg/mL), brain (SF-295, 
GI50= 0.0052 μg/mL), and melanoma (SK-MEL5 GI50= 0.0033 μg/mL) (Nakao et al., 
1998), homodolastatin 16 (76), as a higher homologue of dolastatin 16 (75), exhibited 
moderate activity against esophageal (WHCO1 IC50=4.3 μg/mL and WHCO6 IC50=10.1 
μg/mL) and cervical cancer cell lines (ME180 IC50=8.3 μg/mL). One possible reason for 
the difference in their anticancer activities resulted from the different cancer cell lines 
used for homodolastatin 16 (76) and dolastatin 16 (75). Unfortunately, the comparative 
analysis using esophageal and cervical cancer cell lines was carried out because the 
Davies-Coleman’s group had no dolastatin 16 (75).   
          Examination of the mixed assemblages of Lyngbya majuscule and Schizothrix sp. 
from the Fijian Islands led to the isolation of somamides A (77) and B (78) which are 
analogues in structure to symplostatin 2 (80) and dolastatin 13 (79) (Nogle et al., 2001b; 
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Pettit et al., 1989; Harrigan, et al., 1999). Dolastatin 13 previously been reported from 
marine invertebrates, including the sea hare, D. auricularia, well known for its ability to 
accumulate compounds acquired from its diet of cyanobacteria (Harrigan, et al., 2000). 
Thus, isolation of these depsipeptides provides further evidence that such metabolites are 
truly of cyanobacterial origin. So far dolastatin 13 has been found to strongly inhibit  
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Dolastatin 13 (79)                                                                 Symplostatin 2 (80) 
 
growth of the PS cell line derived from pig kidney and exhibit an ED50 value of 
0.013μg/mL, whereas dehydrodolastatin 13 proved to be marginally inactive in this 
system and revealed the first structure/activity insight. Pig kidney cells of the PS line 
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have proved useful for the study of group B arboviruses (Miller et al., 1969; Westaway, 
1966). There is no report about the bioactivity of somamide A (77) and B (78). 
          Four depsipeptides, wewakpeptins A-D (81-84), were isolated from the marine 
cyanobacterium Lyngbya semiplena collected from Papua New Guinea (Han et al., 2005). 
The wewakpeptins represent an unusual arrangement of amino and hydroxy acid subunits  
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Wewakpeptins A (81) R=CH2C≡CH                                 Wewakpeptins C (83) R=CH2C≡CH 
Wewakpeptins B (82) R=CH2CH2CH3                              Wewakpeptins D (84) R= CH2CH2CH3 
 
relative to known cyanobacterial peptides, and possess a bis-ester, a 2,2-dimethyl-3-
hydroxy-7-octynoic acid (Dhoya) or 2,2-dimethyl-3-hydroxyoctanoic acid (Dhoaa) 
residue, and a diprolyl group reminiscent of dolastatin 15. Wewakpeptin A (81) and B 
(82) were the most cytotoxic among these four depsipeptides with an LC50 of 
approximately 0.4 μM to both the NCI-H460 human lung tumor and the neuro-2a mouse 
neuroblastoma cell lines. Intriguingly, wewakpeptins C (83) and D (84) were 
approximately 10-fold more toxic than A and B to these cell lines. 
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Wewakazole (85) 
 
          Examination of a Papua New Guinea collection of Lyngbya majuscule led to the 
discovery of a cyclic dodecapeptide, wewakazole (85) (Nogle et al., 2003). Wewakazole 
derives solely from amino acids and features three oxazole units which originate from 
serine. There was no report on the biological activity of wewakazole.  
          Lyngbyastatin 3 (86) and desmethoxymajusculamide C (87) were isolated from 
Lyngbya majuscule collected in Apra Harbor, Guam (Williams et al, 2003a) and Fijian 
(Simmons et al., 2009). The absolute configurations of the two unusual amino acid 
residues, the 3-amino-2-methylhexanoic acid (Amha) and 4-amino-2,2-dimethyl-3-
oxopentanoic acid units (Adoa) in lyngbyastatin 3 (86), have been established by 
chemical degradation. The cyanobacterial compounds, lyngbyastatin 3 (86), 
lyngbyastatin 1 (88), and dolastatin 12 (89), are mixtures of Adoa epimers [R (major) and 
S (minor)], whereas the structurally related majusculamide C (90) is a single diastereomer 
with an S-Adoa unit. The presence of a minor diastereomer obviously broadens the 2D 
NMR and 1D TOCSY spectra of 86, 88, and 89 considerably, but it has also been 
suggested that the R- and S-Adoa diastereomers probably have appreciably different 
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amounts of cis and trans conformers around the (Adoa)-(N-methyl-alanine) bond. Also in 
the case of the R-Adoa compounds, the overall shape of the cis and trans conformers 
differs significantly. All of these factors likely contribute to the unusual degree of 
broadness in the NMR spectra. The doubling and broadening of several specific 1H and 
13C NMR signals were not observed in the spectra for desmethoxymajusculamide (87), 
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Lyngbyastatin 3 (86)     
R1=Me, R2=Me, R3=OMe, R4=i-Bu 
 
Desmethoxymajusculamide (87)  
R1=H, R2=H, R3=H, R4=i-Bu 
 
Lyngbyastatin 1 (88)    
R1=H, R2=Me, R3=OMe, R4=i-Bu 
 
Dolastatin 12 (89)  
R1=H, R2=Me, R3=H, R4=i-Bu 
 
Majusculamide C (90) 
R1=H, R2=H, R3=OMe, R4=sec-Bu 
 
thus suggesting the presence of a single Adoa epimer. The pure compound 86 had IC50 
values of 32 and 400 nM against KB and LoVo cell lines, respectively. When tested in 
vivo against colon adenocarcinoma #38 or mammary adenocarcinoma #16/C in mice, 86 
was poorly tolerated and exhibited only marginal or no antitumor activity. 
Desmethoxymajusculamide (87) and its ring-opened form (generated by breaking the 
ester bond) demonstrated equivalent efficacy and solid tumor selectivity against four cell 
lines, including HCT-116, H-460, MDA-MB-435 and Neuro-2A. HCT-116 was the most 
sensitive cell line, with IC50 values of 20 and 16 nM, respectively. These finding was 
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discordant with the common viewpoint that the cyclic form is the bioactive form of the 
many peptides.  
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Lobocyclamide A (91)                                                  Lobocyclamide B (92) R=Et 
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Hormothamnin (94) 
 
          The in vitro antifungal activity against Candida albicans of methanol extracts from 
Lyngbya confervoides led to the isolation of lobocyclamides A-C (91-93) (MacMillan et 
al., 2002).  Lobocyclamide A (91) was very similar to the known peptides hormothamnin 
(94) isolated from Hormothamnion enteromorphoides (Gerwick et al., 1992) and 
laxaphycin A, isolated from the terrestrial cyanobacterium Anabaena laxa (Frankmölle et 
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al., 1992a&b; Bonnard et al., 1997). Lobocyclamides A-C (91-93) exhibited modest 
antifungal activity when tested against fluconazole-resistant fungi C. albicans 96-489 
(150 µg/disk, 91; 7 mm zone; 92, 8 mm; 93, 10 mm) and C. glabrata (92, 6 mm; 93, 8 
mm, each at 150 µg/disk) in disk diffusion assays on Saboraud agar plates or microbroth 
dilution assay (C. albicans 96-489 MIC 91, 100 µg/disk; 92, 30-100 µg/mL). Mixtures of 
lobocyclamides 91 and 92 exhibited significant synergism with higher activity (e.g., 1:1 
mixture of 91 + 92, MIC 10-30 µg/mL) than either of the pure compounds alone. A 
1.1.3 Cyclic polypeptides with branches  
arine Lyngbya 
similar phenomenon also noted by Moore and co-workers for the laxaphycins A and B 
(Frankmölle et al., 1992a).  
          Tiglicamides A-C (95-97) were discovered from the Florida m
confervoides, with their analoues largamides A-C (98-100) (Matthew et al., 2009a and 
2009b). Tiglicamides A-C (95-97) and largamides A-C (98-100) differ from each other 
by one amino acid residue within the cyclic core structure, suggesting an unusually 
relaxed substrate specificity of the nonribosomal peptide synthetase that is the putative 
biosynthetic enzyme responsible for the corresponding amino acid incorporation. 
Tiglicamides A-C (95-97) moderately inhibited porcine pancreatic elastase in vitro with 
IC50 values from 2.14 to 7.28 µM, two to three orders of magnitudes less potent against 
the same enzyme or other mammalian elastases than lyngbyastatins 4–7 (108-111). The 
activities of two other serine proteases tested (chymotrypsin, trypsin) were not 
compromised by compounds 95-97 at concentrations up to 50 µM. These results are 
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consistent with those previously reported for their analogues, largamides A-C (98-100). 
The corresponding largamide methyl esters 101-103 retained low-micromolar inhibitory 
activity, indicating that the carboxylic acid residue is not a requisite element for 
elastaseinhibitory activity. 
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Name R1 R2 Name R1 R2 
Tiglicamide A  4-(OH)PhC2H4- H 
(95) 
Tiglicamide B  
(96) 
PhCH2- H 
Largamide A 
ester (101) 
i-Bu CH3 
2H4- 
methyl ester (102) 
4-(OH)PhC3H5- CH3 
)PhC3H5- 
methyl ester (103) 
4-(OH)PhC4H8- CH3 
        The investigation of the marine cyanobacterium Lyngbya confervoides collected 
methyl 
Tiglicamide C 
(97) 
CH3SO C H 
Largamide A  
(98) 
i-Bu H 
Largamide B 
Largamide B  
(99) 
4-(OH H 
Largamide C  
 (100)
4-(OH)PhC4H8- H 
Largamide C 
 
 
 
  
from the southeastern coast of Florida led to the isolation of 3-amino-6-hydroxy-2-
piperidone (Ahp) containing peptolide, pompanopeptin A (104), and a novel cyclic 
pentapeptide, pompanopeptin B (105) (Matthew et al., 2008a). Pompanopeptin B (105) 
contains N-methyl-2-amino-6-(4’-hydroxyphenyl) hexanoic acid (N-methyl-Ahpha),  
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structurally related to carboxypeptidase-A inhibitors anabaenopeptins I (106) and J (107) 
isolated from the cyanobacterium Aphanizomenon flos-aquae in which L-leucine/L-
phenylalanine and N-methyl-L-alanine residues were replaced by L-Htyr and N-methyl-L-
Ahpha, respectively (Murakami et al., 2000). Pompanopeptin A (104) selectively 
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Anabaenopeptin I (106)                                                               Anabaenopeptin J (107) 
 
hibited trypsin over elastase and chymotrypsin, with an IC50 value of 2.4 mM; in
selectivity is conferred by an arginine residue in the cyclic core. 
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          Lyngbyastatins 4-6 (108-110), three depsipeptides containing the unusual amino 
acid homotyrosine and a 3-amino-6-hydroxy-2-piperidone (Ahp) or 3-amino-6-methoxyl-
2-piperidone (Amp) residue, were isolated from the marine cyanobacterium Lyngbya 
confervoides off the Florida Atlantic coast (Matthew et al., 2007; Taori et al., 2007). A 
sample of the marine cyanobacterium Lyngbya sp. collected from a mangrove channel at 
Summerland Key in the Florida Keys produced two lyngbyastatin analogues, termed 
lyngbyastatin 7 (111) and a previously identified cyanobacterial metabolite somamide B 
(78) (Taori et al., 2007; Nogle et al., 2001b). Lyngbyastatin 4-7 (108-111) and somamide 
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Lyngbyastatin 7 
(111) 
 
B (78) selectively inhibit elastase and chymotrypsin in vitro over another serine protease, 
trypsin with IC50 values of 3.2~13.9 nM and 2.5~4.3 µM, respectively. Along with 
lyngbyastatin 4-7, somamide B and scyptolin A, numerous related Ahp-containing 
cyanobacterial metabolites are assumed to be enzyme substrate mimics to inhibit serine 
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proteases (Matern et al., 2003). Since the Abu moiety appears to contribute strongly to 
the observed selectivity for elastase (S1 subsite = recognition pocket), the cyclic core 
structure for 108-111 represents a potent inhibitor prototype. The residues Abu (2-amino-
2-butenoic acid), Thr, Htyr (homotyrosine) and Ala bind at subsites through S1 to S4 of 
the enzyme. The side chain of component amino acids in related inhibitors, such as 108-
111, has been postulated to provide additional interaction points for hydrogen bonding 
with the enzyme. The Thr unit that forms the ester bond to yield the cyclodepsipeptide 
core occupies the S2 subsite of the protease. The two consecutive residues, Htyr and Ala, 
located N-terminal to this Thr residue are important determinants for efficient elastase-
inhibitor complexes based on the co-crystal structures for FR901277 and scyptolin A 
with the enzyme (S3 and S4 subsites). However, comparable bioassay data for 
cyclodepsipeptides 108-111 indicate that the corresponding compositional difference in 
the side chain between 108 and 111 (Htyr-Ala) versus 110 and 111 (Gln-Ha/Ba) is 
overall less influential on the elastase-inhibitory activity. Remarkably, the fact that the 
protease-inhibitory activity is retained in the O-methylated (Amp) derivative, 
lyngbyastatin 6 (110), demonstrates that the hydroxyl proton in the Ahp unit is not 
critical for the inhibition of elastase or chymotrypsin. 
          Two cyclodepsipeptides, kempopeptins A (112) and B (113), were isolated from a 
marine cyanobacterium Lyngbya sp. from the Florida Keys (Taori et al., 2008). This 
Lyngbya sp. previously afforded the structurally related potent elastase inhibitors 
lyngbyastatin 7 (111) and somamide B (78). Many Ahp-containing cyclodepsipeptides 
isolated from cyanobacteria are known inhibitors of serine proteases such as elastase, 
chymotrypsin, and trypsin. Kempopeptin A (112) inhibited elastase (IC50=0.32 μM) with 
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a slight selectivity over chymotrypsin (IC50=2.6 μM). However, kempopeptin B (113) 
inhibited only trypsin activity (IC50=8.4 μM). These results are in accordance with 
previous crystallographic and structure-activity relationship data, suggesting that the 
amino acid residue between Thr and Ahp binds to the enzyme’s specificity pocket and 
thus plays an important role in determining the selectivity toward serine proteases 
(Linington et al., 2008). A hydrophobic amino acid at the positions of Thr and Ahp 
commonly confers preference for chymotrypsin and elastase inhibition (leucine in 112), 
while a basic amino acid such as lysine or arginine is necessary for trypsin inhibition 
(lysine in 113). The discovery of four different protease inhibitors with three distinct 
 
N
H
O
HN
N
H
N
O
OO
NO
O
O
HO
N
H
OH
H
N
N
O
O
HO O
N
H
O
HN
N
H
N
O
OO
NO
O
O
HO
N
H
O
H
N
O
OBr
NH2
 
kempopeptin A (112)                                                   kempopeptin B (113) 
 
selectivity profiles from a single homogeneous cyanobacterial collection illustrates the 
potential of cyanobacteria to execute their own combinatorial biosynthesis and structure 
optimization. While the role of these protease inhibitors in nature is not fully understood, 
a defensive function against other microorganisms or consumers is probable. 
          Pahayokolides A-B (114-115) and lyngbyazothrins A-D (116-119) were produced 
by a freshwater Lyngbya sp. isolated from the Florida Everglades and the cultured 
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Lyngbya sp. 36.91 respectively (An et al., 2007; Zainuddin et al., 2009). Pahayokolides A 
and B contain the same cyclic undecapeptide core and pahayokolide A contains a pendant 
N-acetyl-N-methyl leucine moiety which is absent in pahayokolide B. The pahayokolides 
are remarkably similar in structure to schizotrin A (122), cyclic peptides isolated from 
Schizotrix sp. (Pergament et al., 1994). Z-dehydrobutyrate, threonine, homophenylalanine 
and N-acetyl-N-methyl leucine of pahayokolide A replace the valine, serine,  
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homotyrosine methyl ether and N-butyroyl-N-methyl alanine of schizotrin A, 
respectively. The lyngbyazothrins are analogous in structure with tychonamides A (120) 
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and B (121) isolated from Tchyonema sp. (Mehner et al., 2008). All the pahayokolides, 
lyngbyazothrins and schizotrin A have an unusual β-amino acid, 3-amino-2,5,7,8- 
tetrahydroxy-10-methylundecanoic acid (Athmu). To the best of our knowledge, this 
amino acid has not been observed elsewhere. However, a similar β-amino acid, 3-amino- 
2,5,7,-trihydroxy-8-phenyloctanoic acid, has been recently identified in tychonamides A 
and B. Like pahayokolide A, tychonamides A and B contain a pendant N-acetyl-N-methyl  
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Schizotrin A (122) 
 
leucine connected via an ester linkage to the 5-hydroxy group of the β-amino acid. 
Pahayokolide A inhibits a number of cancer cell lines over a range of concentrations 
(IC50 varied from 2.13 to 44.57 μM). Pahayokolide A was acutely toxic to zebrafish 
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embryos (LC50=2.15 μM), however, only marginally toxic against brine shrimp at the 
highest concentrations tested (1 mg/mL) (Berry et al., 2004). The mixture of 
lyngbyazothrins A (116) and B (117) showed only low antimicrobial activity against 
Micrococcus flaVus, whereas the mixture of lyngbyazothrins C (118) and D (119) was 
active against Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and Serratia 
marcescens. It seems that the acyl residue at C-5 of the Aound unit plays an important 
role in antimicrobial activity. This assumption was supported by the activity and structure 
of pahayokolide A, where the 5-hydroxy group is also substitute by N-acetyl-N-methyl-
leucine. 
          Various polypeptides isolated from Lyngbya species have been reviewed and their 
bioactivities discussed. It is common that cyanobacteria, including Lyngbya, often 
produce more than one member of a certain structural class. This phenomenon is partially 
a result of relaxed specificity of biosynthetic enzymes (Magarvey et al., 2006). 
Particularly, not only polyketide synthases (PKS) of prokaryotes can show considerable 
substrate tolerance (Watts et al., 2007), but also adenylation domains of non-ribosomal 
peptide synthetase (NRPS) may accept different amino acids within a group of polar or 
nonpolar  amino acids (Challis et al., 2000). Natural structural diversification may also be 
the result of slight genetic variation or a slightly changed environment. 
 
1.1.4 Absolute configuration of peptides  
       To resolve the structure of polypeptides, the natural products are characterized with 
an amino acid analysis, mass spectrometry and NMR. Full assignment of the 1H- and 13C- 
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NMR chemical shifts is achieved on the basis of 2D-NMR experiments including 
TOCSY (total correlated spectroscopy) and HMBC (heteronuclear multiple bond 
correlation experiment). The 2D TOCSY spectrum identifies the chemical shifts of pairs 
of protons that are within the same amino acid and unknown amino acids. The sequence 
of the component is deduced from HMBC. The J-based configuration analysis is proven 
to be practical for natural products with complicated structures (Matsumori et al., 1999).  
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Figure 1 ­ 1.  The reaction of D, L-FDLA with amino acids 
 
The absolute configuration of the secondary alcohol is established by Marfey’s method or 
advanced Marfey’s method. It is difficult to apply Marfey’s method to a peptide 
containing non-proteinogenic amino acids when standards are not available. The 
advantage of advanced Marfey’s method over Marfey’s method is that the former does 
not require authentic D and L standards. 
          The basis of the advanced Marfey’s method is shown in Fig. 1-1. The L-FDLA (1-
fluoro-2,4-dinitrophenyl-5-L-leucinamide) derivatives of D-amino acids (D-L type; the 
first letter refers to amino acids and the second letter refer to FDLA) are diastereomers of  
the L-FDLA derivatives of L-amino acids (L-L type). Generally the diastereomers have 
different retention times during chromatography. In this method, the resolution of D- and 
L-amino acid derivatives with FDLA results from the difference in the hydrophobicity of 
the diastereomeric derivatives. The hydrophobic difference is a result of the relative 
arrangement of the two hydrophobic substituents at both Cα of the test amino acids 
(except Gly) and L-leucine of the L-FDLA. The FDLA derivative of the cis (Z)-type 
arrangement interacts more strongly with ODS silica gel and has a longer retention time 
than that of the trans (E)-type arrangement. Therefore, the trans (E)-derivatives (L-L and 
D-D) are usually eluted first from the column. The relationships between L-D types and 
D-L types, and between D-D types and L-L types are enantiomeric. Each pair of 
enantiomers shows the same retention times. The retention times of the aa-FDLA 
derivatives on C-18 chromatogram is: L-L = D-D < L-D = D-L (Kiyonaga, 1997). 
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 1.2 Results and Discussion 
 
1.2.1 Absolute configuration of pahayokolides A and B 
          Pahayokolides A (114) and B (115) are two branched cyclic peptides produced by 
the fresh water cyanobacterium Lyngbya sp. strain 15-2 from the Florida Everglades. The 
absolute configuration of the component amino acids in pahayokolides A and B were  
 
 
Figure 1 ­ 2. HPLC/PDA chromatogram of standard amino acid mixture derivatized with D,L-
FDLA.  
Assignments are made for derivatives with L-FDLA. 
 
determined using the advanced Marfey’s method. The resulting amino acid derivatives 
are separated by the C18 reverse-phase HPLC, and detected by PDA UV at 340 nm and 
mass spectrometry. In order to optimize the HPLC condition, authentic D and L amino 
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acid standards were derivatized with L-FDLA and analyzed on HPLC/PDA, with the 
exception of Athmu and N-Me-D-leucine which were not commercially available (Table 
1-1, Fig. 1-2). In the case of N-methyl-leucine only the L isomer was commercially 
available. According to the Marfey’s method, the derivative of N-Me-D-leucine with L-
FDLA may be replaced with its enatiomer, the derivative of N-Me-L-Leu with D-FDLA, 
because both of them had the same retention time on the C18 HPLC column. 
 
Table 1 ­ 1. Availability of amino acids standards and reactions with FDLA 
Standards 
 
Availability 
 
FDLA 
 
L-Ser 
 
Yes L-FDLA ⁄ 
D-Ser 
 
Yes L-FDLA ⁄ 
L-Thr 
 
Yes L-FDLA ⁄ 
D-Thr 
 
Yes L-FDLA ⁄ 
L-Athmu 
 
No ⁄ ⁄ 
D-Athmu 
 
No ⁄ ⁄ 
L-Glu 
 
Yes L-FDLA ⁄ 
D-Glu 
 
Yes L-FDLA ⁄ 
L-Pro 
 
Yes L-FDLA ⁄ 
D-Pro 
 
Yes L-FDLA ⁄ 
L-Phe 
 
Yes L-FDLA ⁄ 
D-Phe 
 
Yes L-FDLA ⁄ 
L-Homophe 
 
Yes L-FDLA ⁄ 
D-Homophe 
 
Yes L-FDLA ⁄ 
N-Me-L-Leu 
 
Yes L-FDLA D-FDLA 
N-Me-D-Leu 
 
No ⁄ ⁄ 
Gly Yes L-FDLA ⁄ 
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          As expected, the Marfey analysis supported the presence only of the amino acids 
indicated in the structures of pahayokolides A (114) and B (115) (Fig. 1-3). The absolute 
configuration was assigned as follows using PDA detector at 340 nm: L-serine, D-
glutamine, and L-proline (2), respectively. In the hydrolysis process, free glutamine in the 
hydrolysate was converted into free glutamic acid by hydrolysis of the amide linkage.  
 
 
 
Figure 1 ­ 3. HPLC/PDA analysis of pahayokolide A hydrolysates derivatized with D,L-FDLA (top) 
and L-FDLA (bottom).  
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Dhb (dehydrobutyrate) was not stable as a free amino acid; therefore, it could not be 
derivatized with L-FDLA standard and remained undetected in the amino acid analysis 
(Dahlmann, et al., 2003). Comparison of the diastereomeric derivatives of N-methyl-L-
leucine prepared with both L-FDLA and D-FDLA, with the L-FDLA derivatives of the 
acid hydrolysates of pahayokolides A (114) and B (115), indicated that pahayokolide B 
(114) differed from pahayokolide A (115) in possessing an N-methyl-leucine.  
 
 
 
Figure 1 ­ 4. HPLC/PDA chromatogram of pahayokolide A hydrolysate derivatized with L-FDLA 
and spiked with N-Me-L-Leucine derivatized with L-FDLA (top) and D-FDLA (bottom). 
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          The separate experiments, in which the diastereomeric derivatives of N-methyl-L-
leucine with L-FDLA and D-FDLA were separately spiked into the pahayokolide A 
hydrolysate, indicated that the presence of both N-methyl-L-leucine and its D isomer in 
pahayokolide A (Fig. 1-4). However, the D/L ratio was lower under milder hydrolysis 
conditions. When pahayokolide A was hydrolyzed in 6M HCl, the L: D ratio of N-methyl-
leucine was 2.75:1. Hydrolysis of pahayokolide A in 4M HCl, resulted in a L: D ratio of 
5.5:1. This possibly resulted from the acid sensitivity of the N-methyl-leucine residue. It 
was concluded that the D isomer arose from partial racemization of N-methyl-L-leucine. 
A similar observation was made for the tychonamides (Mehner et al., 2008). 
 
 
Figure  1  ­  5. HPLC/PDA chromatogram of pahayokolide A hydrolysate derivatized with L-FDLA 
and spiked with D,L-Homophe derivatized with L-FDLA. 
 
          The retention times for the L-FDLA derivatives of N-methyl-L-leucine and L-
homophenylalanine were close at 47.3 and 47.7 min., respectively. In separate 
experiments, the L-FDLA derivatized pahayokolide A hydrolysate was spiked with the L-
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FDLA derivatives of N-methyl-L-leucine or L-homophenylalanine, confirming the 
presence of N-methyl-L-leucine and the absence of L-homophenylalanine (Fig. 1-5).  
 
 
Figure 1 ­ 6. HPLC/PDA chromatogram of pahayokolide A hydrolysate derivatized with L-FDLA 
and spiked with D-Phe derivatized with L-FDLA. 
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Figure 1 ­ 7. Mass chromatograms of the L-FDLA derivatives of pahayokolide A hydrolysate 
monitored at the m/z values of the M-1 ions (A, m/z 572, L-Phe; B, m/z 552, N-Me-D,L-Leu; C, m/z 
586, D-Homophe) ions using ESI LC/MS in negative ion mode 
 
Similarly, the retention times for the L-FDLA derivatives of D-phenylalanine and N- 
methyl-D-leucine were very close at 50.0 and 50.2 min. respectively. In separate  
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Figure 1 ­ 8. Mass chromatograms of the L-FDLA (A-D) and D,L-FDLA (E) derivatives of 
pahayokolide A hydrolysate monitored at the m/z values of the M-1 ions (A, m/z 512, L-Ser; B, m/z 
526, L-Thr; C, m/z 554, D-Glu; D, m/z 686, D-AthmU and E, m/z 686, D-AthmU) using ESI LC/MS in 
negative ion mode. 
 
experiments, the L-FDLA derivatized pahayokolide A hydrolysate was spiked with the L- 
FDLA-D-phenylalanine derivative and the D-FDLA-N-methyl-L-leucine derivative, 
confirming the presence of N-methyl-D-leucine and the absence of D-phenylalanine (Fig. 
1-6). Marfey’s analysis using MS confirmed the assignments: L-phenylalanine, N-
methyl-L-leucine and D-homophenylalanine (Fig. 1-7). 
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R= O
N
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N-acetyl-N-methyl-L-leu 
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L-Thr L-Ser
D-Gln
D-Athmu
D-Homophe
 
 
 
Pahayokolide B   R=H 
 
Figure 1 ­ 9. The absolute configuration of pahayokolides A and B 
 
          The absolute configuration at Cβ of Athmu was tentatively assigned as R (or D) by 
Marfey’s analysis with ESI-MS (electrospray ionization mass spectrometry) (Fig. 1-8 D, 
E). The assignment was based on relative retention times of the diastereomeric Athmu 
derivatives, assuming that L-FDLA-L-Athmu elutes before L-FDLA-D-Athmu. The 
absolute configuration at Cβ of two similar α-hydroxy-β-amino acids, 3-amino-2,5,9-
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trohydroxy-10-phenyaldecanoic acid (Ahda) (Helms et al., 1988) and 3-amino-2,5-
dihydroxy-8-phenyloctanoic acid (Ahoa) (Fujii et al., 1999), was assigned by this way. 
The FDLA derivative of Athmu was observed only when the hydrolysis was performed  
Table 1 ­ 2. LC/MS analysis of pahayokolides A­D hydrolysates derivatized with D,L­FDLA and 
L­FDLA  
Pahayokolide A 
hydrolysates 
+ D,L-FDLA 
Pahayokolide A 
hydrolysates 
+ L-FDLA 
Pahayokolide B 
hydrolysates 
+ L-FDLA 
Pahayokolides C&D 
hydrolysates 
+ L-FDLA 
 
[M+TFA-H]- TR 
(min) 
[M+TFA-H]- TR 
(min) 
[M+TFA-H]- TR 
(min) 
[M+TFA-H]- TR 
(min) 
L-Athmu ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
D-Athmu 
686 14.9 
16.0 686 16.2 686 17.9 686 17.6 
L-Ser 512 14.5 512 15.2 512 15.5 
D-Ser 
512 15.4 
16.3 ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
L-Thr 526 14.6 526 16.0 526 15.4 
D-Thr 
526 15.4 
22.7 ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
L- Glu 18.0 ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
D-Glu 
554 
19.7 554 19.0 554 21.0 554 20.0 
L-Pro 24.1 522 24.6 522 24.8 522 24.4 
D-Pro 
522 
31.9 ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
L-Phe 39.4 572 39.3 572 40.8 572 40.2 
D-Phe 
572 
45.8 ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
N-Me-L-Leu 42.0 552 41.6 552 42.5 552 42.0 
N-Me-D-Leu 
552 
45.6 552 45.0 552 46.0 552 45.5 
L-Homophe 42.6 ⁄ ⁄ ⁄ ⁄ ⁄ ⁄ 
D-Homophe 
586 
49.4 586 47.7 586 49.0 586 48.2 
Gly 482 23.7 482 24.2 482 24.4 482 24.0 
FDLA 427 35.8 427 35.7 427 35.9 427 35.5 
M = amino acid + FDLA.  
 
in 4M HCl. When the hydrolysis was carried out in 6M HCl a derivative having a 
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molecular ion at m/z 668 was observed, corresponding to a loss of water from the FDLA-
Athmu derivative. Either one of the alcohols is dehydrated to an alkene or the lactone is 
formed under these conditions. Marfey’s analysis using ESI-MS confirmed L-serine, L-
threonine, D-glutamine (Fig. 1-8 A-C), and was consistent with the other results detected 
using PDA detector (Table 1-2). Except for the absence of N-methyl-L-leucine, the 
component amino acids in pahayokolide B have the same absolute configuration as 
pahayokolide A (Table 1-2, Fig. 1-9). 
 
1.2.2 Pahayokolides C and D is conformers of pahayokolide A 
         Two more cyclic peptides, pahayokolides C and D, were isolated with 
pahayokolides A and B from Lyngbya sp. strain 15-2 (Fig. 1-10).  High resolution mass 
spectroscopy suggested pahayokolides A, C and D had the same m/z (HRESIFTMS m/z 
[M + Na] + 1494.748). Marfey’s analysis indicated that pahayokolides C and D contained  
 
Pahayokolide 
D 
Pahayokolide 
C 
Pahayokolide 
A 
Pahayokolide 
B 
 
Figure 1 ­ 10. HPLC/PDA chromatogram of pahayokolides A-D 
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the same amino acids present in pahayokolides A (Table 1-2). Signal doubling and 
broadening in the 1H and 13C NMR spectra of pahayokolides A indicated the presence of 
isomeric species or slowly interconverting of conformers in solution. Upon heating pure  
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Figure 1 ­ 11. HPLC/PDA chromatogram of pahayokolide A heated at 39 °C and monitored at 220 
nm (red) and 254 nm (blue) at 0, 1, 2, 3, and 48 hours.  
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 Figure 1 ­ 12. HPLC/PDA chromatogram of a complex with pahayokolide C as the major 
component heated at 39 °C and monitored at 220 nm (red) and 254 nm (blue) at 0, 1, 2, 3, and 48 
hours. 
 
 
 
 
Minutes
5 10 15 20 25 30 35 40
m
AU
-20
0
20
40
60
m
AU
-20
0
20
40
60
PDA-220nm
Lyn4+5(major) t=1h 4-13-2007 7-42-22 PM
Retention Time
PDA-254nm
Lyn4+5(major) t=1h 4-13-2007 7-42-22 PM
Area
Minutes
0 5 10 15 20 25 30 35 40
m
A
U
-40
-20
0
20
40
60
80
m
A
U
-40
-20
0
20
40
60
80
PDA-220nm
Lyn4+5(major) t=3h 4-13-2007 10-14-23 PM
Retention Time
PDA-254nm
Lyn4+5(major) t=3h 4-13-2007 10-14-23 PM
Area
Minutes
5 10 15 20 25 30 35 40
m
AU
-20
0
20
40
60
m
AU
-20
0
20
40
60
PDA-220nm
Lyn4+5(major) t=2h 4-13-2007 8-59-26 PM
Retention Time
PDA-254nm
Lyn4+5(major) t=2h 4-13-2007 8-59-26 PM
Area
Minutes
5 10 15 20 25 30 35 40
m
AU
-20
0
20
40
60
m
AU
-20
0
20
40
60
PDA-220nm
Lyn4+5(major) t=1h 4-13-2007 7-42-22 PM
Retention Time
PDA-254nm
Lyn4+5(major) t=1h 4-13-2007 7-42-22 PM
Area
Minutes
0 5 10 15 20 25 30 35 40
m
A
U
-20
0
20
40
60
m
A
U
-20
0
20
40
60
PDA-220nm
Lyn4(major)+5 t=48h 4-16-2007 1-59-09 PM
Retention Time
PDA-254nm
Lyn4(major)+5 t=48h 4-16-2007 1-59-09 PM
Area
C D 
A
Pahayokolide C (major), 39 °C, t=48 h 
Pahayokolide D (major), 39 °C, t=0 h
Pahayokolide D (major), 39 °C, t=1 h
Pahayokolide D (major), 39 °C, t=2 h
C 
D 
C 
D 
C 
D 
D C 
Pahayokolide D (major), 39 °C, t=3 h
58 
 
 Figure 1 ­ 13. HPLC/PDA chromatogram of a complex with pahayokolide D as the major 
component heated at 39 °C and monitored at 220 nm (red) and 254 nm (blue) at 0, 1, 2, 3, and 48 
hours. 
pahayokolides A at 39°C, equilibrium between pahayokolides A, C and D was reached 
after 48 hours (Fig. 1-11). The same equilibrium mixture of pahayokolides A, C and D 
was observed when a mixture of pahayokolides C and D was heated at 39°C for 48 hours 
(Fig. 1-12 and 1-13). All these observations allowed us to conclude that pahayokolides C 
and D were two slowly interconverting conformers of pahayokolide A. 
 
1.3 Materials and Methods 
1.3.1 Culture conditions of Lyngbya sp. strain 15-2 
         Lyngbya sp. strain 15-2 collected from the Florida Everglades was cultured in BG11 
medium supplemented with 0.19 M Na2CO3 buffered with 2-morpholinoethanesulfonic 
acid (MES) at pH 7.2 at 20~22 C under continuous white light for 40 days. 
1.3.2 Purification of pahayokolides A-D 
         Samples of biomass were harvested from cultures of Lyngbya sp. strain 15−2 and 
lyophilized. The freeze-dried biomass was pulverized in liquid nitrogen, and extracted 
in 70% MeOH (in water) at room temperature for two days. Following solvent removal, 
water-soluble constituents were separated by RP18 solid-phase extraction using a stepwise 
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gradient solvent system from 20% MeOH in water to 100% MeOH (Berry et al., 2004). 
The bioactive 80% and 100% MeOH fractions were then separately chromatographed on 
preparative HPLC (Alltech Alltima C18, 10 m, 250  22 mm) using 75% MeOH in H2O 
and detected at 220 nm. Pahayokolides A-D were obtained. The purity of pahayokolides 
was checked on analytical HPLC (Alltech Apollo C18, 5 m, 250 mm  4.6 mm) using 
70% MeOH in H2O and detected at 220 and 254 nm.  
 
1.3.3 Preparation of FDLA derivatives 
         To 40 μL of 2 μM each standard amino acid solution was added 20 μL of 1 M 
sodium bicarbonate, and 80 μL of 1% L- or D-FDLA in acetone. These solutions were 
vortexed and incubated at 40 °C for 60 min. These reactions were quenched by the 
addition of 10 μL of 2 M HCl and stored at 4 °C. According to the Marfey’s method, the 
derivative of N-methyl-D-leucine with L-FDLA could be substituted with the derivative 
of N-methyl-L-leucine with D-FDLA, as the enatiomers will have the same retention time 
on C18 HPLC column.  
         A 100 μg of pahayokolide A or B or a mixture of C and D was hydrolyzed at 110 
°C for 14 h with 500 μL of 4M HCl. This solution was divided into two portions and 
dried with N2 gas. Each portion was derivatized with L- or D-FDLA at 40 °C for 60 min. 
These reactions were quenched by the addition of 10 μL of 2 M HCl and stored at 4 °C.  
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1.3.4 HPLC/PDA conditions  
         The separation of the L- and D,L-FDLA derivatives of pahayokolide A was 
performed on analytical HPLC (Alltech Apollo C18, 5μm , 250 mm ×4.6 mm) using a 
step-wise gradient solvent system (CH3CN: 0.1M TFA=4:6 in 24min, CH3CN: 0.1M 
TFA=1:1 in 25~34min, CH3CN: 0.1M TFA=7:3, after 35min ) at a flow rate of 0.4 
mL/min. The FDLA derivatives were detected by PDA UV detector at 340nm.  
 
1.3.5 ESI LC/MS Conditions  
         All mass spectra were carried out with a single quadrupole mass spectrometer  
 (ThermoQuest Finnigan Navigator) in ESI-mode. The sample probe was set at 400 ◦C 
and 4 kV with an entrance cone voltage of 10V. 
 
1.3.6 Spike-in experiments 
         The L-FDLA derivative of pahayokolide A hydrolysate was spiked with the L-
FDLA derivatives of N-methyl-L-leucine, the D-FDLA derivatives of N-methyl-L-
leucine, the L-FDLA derivatives of L-homophenylalanine and the L-FDLA derivatives of 
D-phenylalanine, separately.  
 
1.4 Conclusions 
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         Determination of absolute configuration is an important part of structure 
elucidation. Many biochemical processes depend on chirality. Proteins contain 
principally L-amino acids. However, certain microorganisms make use of both the L form 
and D form of amino acids. Based on Marfey’s, pahayokolide A, a cyclic cyanobacterial 
peptide isolated from Lyngbya sp. strain 15-2, only contained the amino acids present in 
its given structure and its absolute configuration is as follows: L-proline (2), L-
phenylalanine, L-serine, L-threonine, D-homophenylalanine, D-glutamine, N-methyl-L-
leucine and D-Athmu. Pahayokolides A, C and D showed the same absolute 
configuration as pahayokolide B. It was also confirmed that a pendant N-acetyl-N-methyl 
leucine moiety in pahayokolide A was absent in pahayokolides B and pahayokolides C-D 
were conformers of pahayokolide A.  
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2. Biosynthetic Pathway for the Construction of the 
Pahayokolide A 
 
2.1 Introduction 
 
          The biosynthesis of cyanobacterial peptides has attracted considerable attention not 
only because cyanobacterial peptides represent a potential source for pharmaceutical 
agents, but also because of the risk of exposure to humans as well as animals. 
Cyanobacterial peptide toxins can be synthesized via both ribosomal and nonribosomal 
pathways. In the ribosomal system, one of twenty proteinogenic amino acids is 
specifically activated by the aminoacyl-tRNA synthetase (aaRS) specific for that tRNA 
as aminoacyl-tRNAs and peptide bond formation is directed by the ribosome. 
Subsequently, a peptide bond is formed by the ribosome. Distinct from the traditional 
ribosomal mechanism, some microorganisms, such as bacteria and fungi, assemble small 
peptides (mostly less than 20 amino acids residues) by a nucleic acid-independent 
pathway. In these “non-ribosomal” peptides, the incorporation of a wider range of amino 
acid substrates, for which there exists no specific tRNA, suggests a nonribosomal origin 
of biosynthesis (Sieber et al., 2005). In the 1970s Lipmann et al. found Bacillus sp. 
contained multienzyme complexes which were responsible for the biosynthesis of the 
peptide antibiotics gramicidin S and tyrocidine A, and were similar to fatty acid 
synthetases (Lipmann et al., 1971). In the following years a variety of nonribosomal  
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Figure 2 - 1 Linear, cyclic and branched cyanobacterial peptides and their bioactivities 
  
Grassypeptolide  
 
Lyngbya confervoides, Florida Keys 
 
Grassypeptolide inhibited cancer cell growth (IC50 
=1.0 ~ 4.2 μM.) 
 
(Kwan et al., 2008) 
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Lyngbya majuscule, Isla Bastimentos, Bocas del 
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Carmabin A, dragomabin, and dragonamide A 
showed good antimalarial activity (IC50 = 4.3, 6.0, 
and 7.7 μM, respectively), whereas the nonaromatic 
analogue, dragonamide B, was inactive.  
 
(McPhail et al., 2007) 
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Microcolins A and B 
 
Lyngbya majuscule, a fore reef slope, Pta. Bobos, 
La Blanquilla, Venezuela 
 
Microcolins A and B exhibit potent 
immunosuppressive activity 
 
(Koehn et al., 1992) 
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Lyngbya sp. 15-2, the Florida Everglades 
 
Pahayokolides A and B inhibited a number of 
cancer cell lines over a range of conc. (IC50 = 2.13 ~ 
44.57 μM) depending on the cell-type, marginally 
toxic to brine shrimp only at the highest conc. (1 
mg/mL), acutely toxic to zebrafish embryos (IC50 = 
2.15 μM). 
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peptides have been isolated from microorganisms, including cyanobacteria, originating 
from aquatic and terrestrial habits. Nonribosomal peptides can be more complex than 
ribosomal peptides, and include macrocycles and/or branches (Fig. 2-1). Macrocycles can 
be formed through peptide or ester bonds. In contrast to the ribosomal peptides, the 
cyanobacterial peptides, synthesized by the non-ribosomal pathway may contain a high 
proportion of non-proteinogenic amino acids, such as pseudo, hydroxyl, N-methylated, 
and D-amino acids (Table 2-1) (Marahiel et al., 1997; Stachelhaus et al., 1995a). Some 
bioactive peptides have been used widely in medicine, and biological research, including 
antibiotic (vancomycin), immunosuppressive (cyclosporin A), antiviral (luzopeptin A) 
and antitumor (echinomycin and triostin A) activities.  
           In spite of their diverse structures and broad spectrum of bioactivities, non-
ribosomal peptides share a common mode of biosynthesis. This biosynthetic process is 
performed by multienzyme complexes termed non-ribosomal peptide synthetases 
(NRPSs) (Marahiel et al., 1997). Over the past three decades, significant progress has 
been made in characterizing the architecture of NRPSs and understanding the molecular 
principles of nonribosomal peptide biosynthesis in microorganisms (Schwarzer et al., 
2003; Mootz, 2002; Marahiel et al., 1997). Sequence analysis of genes which encode 
bacterial and fungal NRPSs has provided insight into their molecular architecture 
(Marahiel et al., 1997). Te NRPS acts as the template for the non-ribosomal biosynthesis 
of polypeptides. The NRPS is organized as modules, which are independent enzymatic 
units in an assembly line. One module of an NRPS is responsible for one reaction cycle, 
and incorporates one amino acid into the peptide product (Stachelhaus et al., 1995). It is  
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Table 2 - 1. Representative Examples of Non-proteinogenic Constituents of Peptide Antibiotics  
 
Name Structure Abbre-
viation 
System(s) Organism(s) 
Modified, 
proteinogenic 
amino acids 
    
N-methyl aa 
(e.g. N-methyl 
valine) 
O-
HN
O
 
MeVal Cyclosporine 
enniatin 
Tolypocladium 
niveum 
D-aa (e.g. D-
phenylalanine O-
+NH3
O
 
D-Phe e.g.  
Bacitracin 
gramicidin S 
tyrocidine 
Bacillus 
licheniformis 
Bacillus brevis 
Bacillus brevis 
Non-
proteinogenic 
amino acids 
    
δ-(L-amino 
adipic acid) 
O-
O
O
O-
+NH3
 
Aad ACV-tripeptide 
(precursor of 
penicillin and 
cephalosporin) 
Penicillium 
chrysoogenum 
Aspergillus nidulans 
Streptomyces 
clavuligerus 
2-amino-9,10-
epoxy-8-
oxodecanoic 
acid 
O-
O
O
O
+NH3  
Aeo HC-toxin Cochliobolus 
carbonum 
L-α-amino 
butyric acid 
O-
+NH3
O
 
Abu cyclosporin Tolypocladium 
niveum 
(4R)-4[(E)-2-
butenyl-4-
methyl-L-
threonine] 
O-
+NH3
OOH
 
Bmt cyclosporin Tolypocladium 
niveum 
2,6-diamino-7-
hydroxy-azealic 
acid 
O-
+NH3
OOH
+NH3
OH
O
O-
 
Dha edeine Bacillus brevis 
ornithine 
O-
+NH3
O
H3N+
 
Orn e.g. 
Bacitracin 
gramicidin S 
tyrocidine 
Bacillus 
licheniformis 
Bacillus brevis 
Bacillus brevis 
carboxy acids     
2,3-dihydroxy 
benzoic acid O-
OOH
HO
 
DHB enterobactin Escherichia coli 
D-α-
hydroxyisovaler
ic acid 
O-
OH
O
 
Hiv Enniatin B Fusarium scirpi 
amines     
spermidine H3N+
H
N
+NH3  
Sperm edeine Bacillus brevis 
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possible to predict the final peptide product on the basis of the number and order of these 
modules in the NRPS (Walsh et al., 2001).  
         A typical NRPS module is further subdivided into a set of distinct domains, each 
domain catalyzing a specific reaction. In a single reaction cycle, the biosynthetic steps, 
including substrate recognition, activation as adenylate, covalent intermediate fixation as 
an enzyme-bound thioester, and peptide-bond formation, can be assigned to different 
domains which are connected by flexible linkers (Sieber et al., 2005). A minimal 
elongation module consists of three core domains: a 55 kDa adenylation domain (A 
domain) responsible for substrate selection and activation through ATP hydrolysis 
(Turgay et al., 1992; Stachelhaus et al., 1995a), a 10 kDa downstream peptidyl carrier 
protein domain (PCP domain) for the covalent fixation as a thioester (Stachelhaus et al., 
1996), and a 50 kDa condensation domain (C domain), located upstream of the A domain 
(Stachelhaus et al., 1998). The C domain catalyzes the peptide-bond formation between 
an activated amino acid and a peptidyl-bound intermediate of two adjacent modules (Fig. 
2-2). 
 
2.1.1 Functional domains of non-ribosomal peptide synthetases 
2.1.1.1 Activation by the adenylation domain 
         Non-ribosomal peptide synthesis is initiated by the A domain which recognizes and 
activates the specific amino acid from a substrate pool, by forming the aminoacyl 
adenylate from ATP. Amino acid building blocks are activated by A domains to afford  
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Figure 2 - 2. Domain-catalyzed reactions. 
Domains in action are indicated in red. (A) Recognition and activation of a dedicated amino acid with ATP 
by the A domain. (B) Covalent attachment of the activated aminoacyl adenylate onto the free thiol group of 
the PCP-bound ppan (4’-phosphopantetheine) cofactor. (C) Peptide elongation by the C domain which 
catalyzes an attack of the nucleophilic amine of the acceptor substrate onto the electrophilic thioester of the 
donor substrate. (Stachelhaus, 1998). 
 
68 
 
aminoacyl adenylates at the expense of Mg2+-ATP with release of PPi (pyrophosphate) 
(Figure 2-2A). The A domain belongs to the family of adenylate-forming enzymes which 
also contains aryl-AMP ligases, firefly luciferase, aminoacyl tRNA synthetases and the 
acyl-CoA ligases. The adenylate-forming enzymes catalyze the adenylation of their 
carboxy substrates. In the ribosomal pathways of peptide synthesis, aminoacyl tRNA 
synthetases also activate the amino acid substrate as aminoacyl adenylates. Despite 
synthetases are significantly different in their primary structures (Conti et al., 1996; Onest 
et al., 1995). However, in spite of their low sequence identity of 16%, firefly luciferase 
and the phenylalanine-activating A domain (PheA) of GrsA fold nearly identically 
(Baldwin, et al., 1996; Conti, et al., 1996).   
 
Table 2 ­ 2. Highly Conserved Core Motifs of the A Domain of Peptide Synthetases  
 
Domain Core motifs Consensus sequence 
A1 L(TS)YxEL 
A2 LKAGxAYL(VL)P(LI)D 
A3 LAYxxYTSG(ST)TGxPKG 
A4 FDxS 
A5 NxTEYGP 
A6 (core 3) GELxLxGxG(VL)ARGYL 
A7 (core 4) Y(RK)TGDL 
A8 (core 5) GRxDxQVKIRGxRIELGEIE 
A9  LPxYM(IV)P 
Adenylation 
A10  NGK(VL)DR 
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          Sequence alignments of A domains of all known NRPS show 30-60% sequence 
identity (Turgay, 1992). The expression and crystallization of PheA of GrsA provided 
insight into the 3D structure of the A domain (Marahiel et al., 1997). In the crystal 
structure containing the bound L-phenylalanine, AMP and Mg2+, PheA consists of two 
subdomains showing the large N-termini of ~400 residues and the small C-terminal 
subdomain of ~100 residues, which is connected with a short hinge (Fig. 2-3). Most of 
the residues responsible for substrate recognition are located in the large N-terminal 
subdomain. The complete loss of activity in the deletion studies 
C
A9
A8
A6
N
A4
A5
A7
A1
A2
A3
A10
 
Figure 2 - 3 Ribbon diagram of the phenylalanine-activating A domain (PheA) of gramicidin S 
synthetases I (GrsA).  
The substrates, phenylalanine and AMP are drawn using a space-filling representation. The 10 core motifs 
(A1-A10) are indicated.   
 
suggested that the small C-terminal subdomain is necessary for the activity of the protein 
(Marahiel et al., 1997). The active site is located at the interface between the two 
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subdomains and rotation closes the cleft between them. The substrate enters the active 
site through a channel-like entrance. Each A domain is composed of 10 highly conserved 
core motifs (A1-A10, Table 2-2) which work as ‘functional anchors’ for ATP binding, 
hydrolysis and adenylation of the substrate carboxy moiety (Sieber et al., 2005). Most of 
the 10 core motifs are located around the active site where the substrates are bound (Fig. 
2-3).  
          In contrast to aminoacyl tRNA synthetases, A domains of NRPSs exhibit varying 
degrees of substrate selection at defined positions (Döhren et al., 1997; Kleinkauf et al., 
1996). This NRPS strategy readily increases the diversity of the respective peptide 
products. On the other hand, no significant evolutionary pressure for accurate substrate 
recognition by NRPSs is expected. In the biosynthesis of cyclosporine A, enniatin, 
surfactin, and tyrocidine, the specificity of amino acid incorporation is a function of the 
availability of amino acids in the growth media (Marahiel et al., 1997). The binding 
pocket is located in the unconserved region between core motifs A3 and A6 (Cosmina et 
al., 1993). Within this region, eight amino acids control substrate specificity and can be 
considered the 'codons' of non-ribosomal peptide synthesis. As determined from the 
crystal structure of PheA of GrsA, the hydrophobic binding pocket is closed at the bottom 
by the indole ring of Trp239, bordered on one side by Ala236, Ile330 and Cys331, and by 
Ala322, Ala301, Ile299 and Thr278 on the other side. These eight amino acids located 
between the core motifs A3 and A6 provide a structural basis of substrate recognition in 
the A domains of NRPSs and could be used to predict from the primary sequence the 
specificity of biochemically uncharacterized A domains. 
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2.1.1.2 Intermediate transport by the peptidyl carrier protein 
           The PCP, also called the thiolation domain (T domain) and located downstream of 
the A domain within the NRPS assembly line, is responsible for transporting the 
intermediates to the catalytic centers (Fig. 2-2B). Before reacting with aminoacyl 
adenylate, the apo-PCP requires catalytic activation to its active holoform by 
posttranslational modification. Catalyzed by a 4’-phosphopantetheinyl transferases (4’-
pp-transferases), the 4’-PP moiety of coenzyme A is transferred to the side chain of a 
highly conserved serine residue at the C-terninal region of the PCP (Fig. 2-4) (Marahiel 
et al., 1997). The activity of recombinant holo-PCP with the adjacent A domain can be 
tested by an aminoacylation assay with ATP and radioactive amino acids in vitro (Linne 
et al., 2004).   
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Figure 2 - 4 Posttranslational phosphopantetheinylation 
 
          The solution structure of the third PCP of the B. brevis tyrocidine synthetase was 
solved in 2000 (Weber et al., 2000). The PCP is a distorted four-helix bundle containing 
an extended loop between the first two helices (Fig. 2-5). The cofactor binds with the 
conserved serine residue of the PCP, which is located at the interface between the loop 
and the second helix (Marahiel et al., 1997). There is no evidence for the existence of a 
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binding pocket-like structure for the loaded substrate in the PCP, which is consistent with 
the observation that the PCP lacks substrate selectivity (Weber et al., 2001).  
           Acyl carrier proteins (ACP) from fatty acid and PKSs (polyketide synthetases) 
function similarly to PCPs. PCPs and ACPs fold into almost identical structures, 
however, these two proteins only share sequence homologies in the immediate 
neighborhood of the invariant serine residue. The most obvious difference between PCPs 
and ACPs in that the PCP surface [pI (isoelectronic point) 6~7] is much more polar than 
the ACP surface (pI ~3.8) (Weber et al., 2001).  
 
 
 
 
Figure 2 ­ 5 Structure of the PCP domain 
derived from the third module of the B. brevis 
tyrocidine synthetase. 
 
 
2.1.1.3 Peptide elongation by the condensation domain 
          After activation and covalent binding of the amino acid substrate by the A-PCP 
initiation module, the peptide bond is formed with aminoacyl substrates binding to PCPs 
of the downstream module (C-A-PCP). The condensation is catalyzed by the C domain. 
The free amino group on the downstream aminoacyl-S-PCP attacks the upstream 
peptidyl-S-PCP (Fig. 2-2C). C domains show low sidechain selectivity for the incoming 
peptidyl-S-PCP but high sidechain specificity for the incoming aminoacyl-S-PCP 
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nucleophile (Weber et al., 2001). Both A domains and C domains work as substrate filter 
in non-ribosomal peptide synthesis.  
          C domains share only moderate homology with each other. The C domains present 
at the N-terminus of the amino acid-accepting synthetase are even less conserved than 
internal C domains which are present between two adjacent A-PCP activating modules. 
The core sequences given in the Table 2-3 are more conserved for the internal C doamins 
(de Crécy-Lagard et al.; 1995). One highly conserved core motif C3 (HHXXXDG) in the 
C domain was also found in acyltransferases such as chloramphenicol acetyltransferase 
(CAT), NRPS epimerization and heterocyclization domains (Keating et al., 2002; de 
Crécy-Lagard et al.; 1995). Mutational experiments proved the importance of the second 
histidine in the condensation reaction.  
 
Table 2 ­ 3. Highly Conserved Core Motifs of the C Domain of Peptide Synthetases  
Domain Core motifs Consensus sequence 
C1 SxAQxR(LM)(WY)Xl 
C2 RHExLRTxF 
C3 (His) MHHxISDG(WV)S 
C4 YxD(FY)AVW 
C5 (IV)GxFVNT(QL)(CA)Xr 
C6 (HN)QD(YV)PFE 
Condensation 
C7 RDxSRNPL 
 
           The C domain structure was unavailable until Keating and his co-workers solved 
the crystal structure of VibH (Fig. 2-6) (Keating et al., 2002). VibH of the Vibrio cholera 
vibriobactin synthetase is a monomer with two pseudodimeric domains containing an α β  
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Figure 2 ­ 6 Crystal structure of VibH. 
 A stand alone C domain of the V. cholerae 
vibriobactin synthetase. 
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Figure 2 ­ 7 Suggested mechanism for the condensation/elongation reaction in peptide synthesis. 
 
α sandwich. The conserved HHXXXDG motif is present in a loop at the interface 
between the two domains. His126 can be reached from two different directions of the 
enzyme. As a base, His126 activates the free amino group of the downstream acceptor for 
nucleophilic attack on the upstream thioester. Two amino acid residues attached as 
thioesters to adjacent PCP domains via the cofactor 4’-PP and His126 of the C domain 
are shown (Fig. 2-7). A nucleophilic attack by the incoming amino group on the thioester 
activated carboxyl group of the preceding amino acid is proposed. 
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Figure 2 ­ 8. Crystal structure of Srf TE.  
(α,β-hydrolase fold). 
 
 
2.1.2 Peptide release 
          Upon completion, the mature peptide must be cleaved from the NRPS to make the 
way for the next peptide product. A C-terminal thioesterase (TE) domain of about 250 aa 
catalyzes the deacylation of the most C-terminal PCP and cleaves the final product. In 
some NRPSs of fungal origin, the TE domain is replaced by a special C domain. 
Cyclosporin synthetase, the 1.7-MDa polypeptide responsible for assembly of the fungal 
cyclic undecapeptide immunosuppressant drug, is such an example (Weber et al., 1994). 
In the mechanism of TE catalysis, an ester bond is formed between the conserved serine 
residue of the TE and the C-terminal amino acid of the peptide product.  
          The crystal structure of the surfactin TE (Srf TE) domain represents an obvious 
α/β-hydrolase fold which is characteristic of a large family of proteases, lipases, and 
esterases (Fig. 2-8A, Bruner, et al, 2002). The low homology (10-15% identity) in 
primary sequence of TE domains reflects the broad variety of cyclization strategies. On 
the other hand, the rigid fold of these enzymes ensures the precise alignment for catalytic 
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action. In the structure of Srf TE (Fig. 2-8B), the three essential amino acids (Ser80, 
His207, and Asp107) for the enzymatic activity of the catalytic triad were identified by 
mutational analysis (Tseng, et al., 2002). With the exception of two positive charged side 
chains of Lys111 and Arg120, the cavity is bound mainly by hydrophobic residues. 
Deacylation of the linear intermediate releases a linear peptide by hydrolysis or a cyclic 
product by an intramolecular nucleophile reaction (Fig. 2-9). The oxyanion hole encodes 
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Figure 2 ­ 9 Mechanism of thioesterase domain catalysis.  
a peptide-O-TE acyl-enzyme intermediate is formed by transfer of the peptidyl chain from the 
phosphopantethiene of the terminal peptidyl carrier protein (PCP) to the active site serine of the TE 
domain. For hydrolyzing TE domains, the intermediate is captured by water, generating the linear peptide; 
for cyclizing TE domains, an intramolecular nucleophile captures the intermediate, resulting in a cyclic 
product. 
 
a critical stage of the two different paths. In the release reaction, the negatively charged 
tetrahedral intermediate is stabilized by hydrogen bonds to the amide bonds of the two 
amino acids with positively charged side chains. Hydrolytic cleavage is favored by a 
glycine residue adjacent to one of the two stabilizing amides, leaving only enough space 
for a water molecule to enter with ease during a critical step of catalysis. In contrast, a 
highly conserved proline is at the same position in the cyclizing TE domain, imparting 
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rigidity and favoring the intramolecular pathway. The cyclizing TE domain provides a 
source of structural diversity as a variety of groups can serve as the nucleophile in the 
cyclization reaction including the N-terminal amino group (resulting in head-to-tail 
cyclization) as in the peptide antibiotics tyrocidine and cyclosporine A, a side chain 
nucleophile (resulting in a lipo or amino acid branched cyclic molecule) as in the 
antibiotics bacitracin and daptomycin, and the β-hydroxyl group of a β-hydroxy fatty acid 
as in surfactin A (Fig. 2-10). Many polypeptides, polyketides, and their hybrids have 
macrocyclic structures, including the immunosuppressant cyclosporine, the antibiotics 
erythromycin and daptomycin, and the anticancer agent epothilone. A macrocyclic 
structure is a desirable feature for biologically or pharmaceutically active compounds 
(Stephan et al., 2003). Macrocyclic compounds exhibit greater cell permeability and 
resistance to cellular breakdown, and more favorable conformational orientation 
compared with their linear counterparts (Singh, et al., 2008). Because macrocyclic 
structures are less conformationally flexible than their linear analogues, the former are 
readily constrained to a particular biologically active conformation (Kohli, 2001). The 
conformational constraint that results from cyclization promotes the macrocycles to 
present themselves favorably to the binding region of potential molecular targets and thus 
influence the targeted cellular pathway. Peptidomimetic macrocycles exhibit a 2 to 5 
kcal/mol savings in binding energy when interacting with proteases versus their linear 
counterparts because of their significant conformational restriction (Singh, et al., 2008). 
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Figure 2 - 10. Naturally occurring macrolactones and macrolactams. 
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2.1.3 Modifying domains 
          In addition to the core domains, several modifying domains, such as epimerization 
(E), cyclization (Cy) and N-methylation (N-Mt) domains, are occasionally present in 
non-ribosomal peptide assembly lines and enrich the structural diversity of NRPS 
products (Konz, 1999). 
 
2.1.3.1 Epimerization domain 
          One common structural feature of NRPs is the inclusion of amino acids of D-
configuration. Two strategies have been discovered for incorporation of D-amino acids 
into NRPs (Marahiel et al., 1997). The most common route involves epimerization of the 
Cα-carbon of the PCP-tethered aminoacyl substrate by an integrated 450-amino-acid-long 
E domain to afford a D/L equilibrium (Pfeifer et al., 1995; Stachelhaus et al, 2000). The 
enantio-selective donor site of the downstream condensation domain ensures the specific 
incorporation of only the desired D-amino acid into the growing peptide chain. A 
secondary strategy of D-amino acid incorporation is often observed in fungal NRPSs. For 
example, the A domain of the cyclosporine synthetase incorporates D-Ala provided by an 
external racemase (Hoffmann et al., 1994).  
          The E domain is substrate specific and racemizes noncognate amino acids with 
lower efficiency. At this time a crystal structure of an E domain has not be acquired. 
However, aligment studies show the similarity of the E domain to the C domain. C and E 
domains share a HHXXXDG conserved motif (C3 and E2), in which the second Histine 
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seems to be involved in catalysis (Table 2-4). Moreover, E domains play a crucial role in 
NRPS protein-protein recognition, mainly in bacterial systems (Sieber et al., 2005). 
 
Table 2 ­ 4. Highly Conserved Core Motifs of the Epimerization Domain of Peptide Synthetases  
Domain Core motifs Consensus sequence 
E1 PIQxWF 
E2 (His) HHxISDG(WV)S 
E3 DxLLxAxG 
E4 EGHGRE 
E5 RTVGWFTxxYP(YV)PFE 
E6  PxxGxGYG 
Epimerization 
E7  FNYLG(QR) 
 
2.1.3.2 Cyclization domain 
          Cy domains replace C domains in modules where oxazoline or thiazoline are 
formed and perform both intermolecular condensation and intramolecular 
heterocyclization reactions (Marshall et al., 2002; Keating et al., 2000). In Cy domains, 
the conserved Asp residues in the DXXXXD motif are critical for both condensation and 
heterocyclization (Keating et al., 2000). 4,5-dihydrooxazole, the heterocycle in 
enterobactin is form by two Cy domains (Fig. 2-12). 
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2.1.3.3 N-methyltransferase domain 
          N-methylation significantly contributes to biological activities of non-ribosomal 
peptides and their stability against proteolytic cleavage. N-methylation in NRPSs is 
catalyzed by the 420 amino acids comprising N-Mt domain which is inserted into the 
accompanying A domain. The N-Mt domain contains at least three core motifs (M1-M3, 
Table 2-5). The glycine-rich sequence VL(ED)GxGxG (M1) exhibits significant 
similarity to the common S-adenosylmethionine (SAM) binding site of a heterologus 
class of co-substrate-dependent methyltransferases (Marahiel et al., 1997). Recombinant 
protein and deletion studies reveal that N-methylation takes place at the thioester stage 
before peptide bond formation (Haese et al., 1994; Pieper et al., 1995; Billich et al., 
1987). With the help of the N-Mt domain, the S-methyl group of SAM is transferred to 
the α-amino group of the thioesterified amino acid and S-adenosylhomocysteine is 
released as a reaction byproduct.  
 
Table 2 ­ 5. Highly Conserved Core Motifs of the N­methylation Domain of Peptide Synthetases  
Domain Core motifs Consensus sequence 
M1 VL(DE)GxGxG 
M2 NELSxYRYxAV 
N-methylation 
M3 VExSxARQxGxLD 
 
2.1.4 Deviations from NRPS co-linearity rule 
          The co-linearity rule refers to the 1:1 correspondence between the number of 
modules present and amino acids in the final product with the order of the amino acids in 
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the peptide determined by the order of the modules in the synthetase. In most cases the 
peptide products are co-linear with the number and organization of the modules within 
NRPSs. The starting module only contains A and PCP domains. The typical elongation 
module is organized as C-A-PCP. Usually a TE domain in the terminal module 
hydrolyzes the full peptide from the immediate upstream PCP domain. In the case of an 
iterative NRPSs use their modules iteratively and produce peptides containing repeated 
units (Fig. 2-11). Iterative and linear NRPSs cannot be distinguished by their primary 
sequences. The iterative ester-bond-forming step has not yet been demonstrated 
experimentally. Known iterative enterobacterin and gramicidin S NRPSs show that the 
terminal TE domain controls the multimeration process (Shaw-Reid et al, 1999).It is 
presumed that in most PKS and NRPS enzymes, the rate of acyl chain release from the 
covalent acyl-O-TE domain would be variable. For cyclization catalyzing TE domains 
hydrolysis must be suppressed, and the acyl-O-TE variant must be stable enough to wait 
for capture by a hydroxyl or amide sidechain internal to the natural product acyl chain. In 
EntF the mono DHB (dihydroxybenzoate)–Ser-O-TE (Fig. 2-11, 2) must be relatively 
stable and serve as a waiting room for interdomain acyl transfers of covalent 
intermediates. The free phosphopantetheinylated PCP domain of EntF is reacylated by 
seryl-AMP from the adenylation domain of EntF and the secondary DHB-Ser chain in 
thioester linkage on PCP (Fig. 2-11, 3) is produced through the condensation domain. At 
this point, catalysis of ester-bond formation could occur by attack of the sidechain of the 
seryl moiety on the DHB-Ser-O-TE (Fig. 2-11, 2) onto the carbonyl of the thioester 
linkage of DHB-Ser-S-PCP (Fig. 2-11, 3) to effect ester synthesis, chain translocation 
and generation of the dimeric DHB-Ser-O-DHB-Ser-O-TE  (Fig. 2-11, 4). The trimeric 
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(DHB-Ser)3-O-TE (Fig. 2-11, 5) would result from iteration of the ‘waiting room’ 
proposal. The final product is released through cyclization. However, the alignment of 
iterative and common TE domains failed to explain such an iterative function. 
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Figure 2 ­ 11. Enterobactin NRPS as an example for iterative NRPS.  
Proposed mechanism for elongation, lactonization and ternimiation of enterobactin by EntF TE domain.  
non-ribosomal peptide consisting of n amino acids, the core domains within its linear NRPS are arranged in 
the order A-PCP-(C-A-PCP)n-1-TE. However, some exceptions, such as iterative and nonlinear NRPSs, 
don’t follow the co-linearity rule (Mootz, 2002).The TE domain serves as a ‘waiting room’ for interdomain 
acyl transfers of covalent intermediates (species 1-5) fron the upstream peptidyl carrier protein and it is the 
putative location for intermolecular cyclotrimerization to release enterobactin.  
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Figure 2 ­ 12 Vibriobactin NRPS as an example for nonlinear NRPS 
 
          In addition to iterative NRPSs, the putative nonlinear NRPSs are not rare. 
Nonlinear peptide products result from unusual internal cyclization or branch-point 
syntheses. Vibriobactin synthetase (vibF) contains six-domain (Cy1-Cy2-A-C1-PCP-C2) 
(Fig. 2-12). The free, soluble, small norspermidine molecule is used as nucleophiles for 
the carbonyl groups of the intermediates of DHB and threonine. The C domain of vibH 
transfers the first DHB from DHB-S-vibB to the amine group of a norspermidine 
molecule. VibF only contains one A domain and one PCP to build two Dhb-threonyl-S-
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PCPs for each final product, but two Cy domains and two C domains. It is believed that 
each C domain catalyze transfer one Dhb-Oxa on the norspermidine acceptor because 
recognition of the middle and terminal amine might require a dedicated catalyst. Cy2 is 
capable of and limited to the condensation (amide bond formation) step of the three-step 
heterocyclization process, while Cy1 is capable of and limited to the final processing 
(cyclization/dehydration) steps to the completed heterocycle (Marshall et al., 2002). 
 
2.1.5 Polyketide synthetases associated with nonribosomal peptide synthesis 
          Polyketide synthetases (PKS) are multimodular enzyme complexes which share a 
similar mode of product assembly as NRPSs and also possess a modular arrangement 
(Katz et al., 1993). Instead of assembling amino acids, PKSs link acetate and proponate 
as the primary building block. PKSs can be divided into three classes (Gokhale, et al., 
2001). Type I PKSs are organized into modules with each module responsible for one 
cycle of chain elongation. Type I PKSs produce nonaromatic polyketides and currently 
represent all cyanobaterial PKSs to date. Type II are only found in bacteria and typically 
involved in the biosynthesis of aromatic polyketides. The individual domain of type II 
PKSs are used iteratively for each cycle of chain elongation. Type III PKSs are 
homodimeric condensation enzymes which are responsible for biosynthesis of flaonoids 
and chalcone compounds (Barrios-Llerena et al., 2007). Typically, a module of the type I 
PKS contains at least an acyltransferase (AT) domain for extender unit loading, an acyl 
carrier protein (ACP) domain for holding the growing polyketide chain as a thiol ester, 
and a β-ketoacyl synthetase (KS) domain catalyzing the decarboxylative condensation 
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between the extender unit and the growing polyketide chain. Both of the PCP for PKSs 
and the ACP for NRPSs are post-translationally modified by 4’-pp-transferases. The 
growing acyl chain can modified by β-ketoreductase (KR), enoyl reductase (ER), 
dehydratase (DH) or methyl transferase (MT) doamins before the final polyketide 
product is released from the assembly enymze via the thioesterase (TE) domain (Du et 
al., 2001). Because of  the similar molecular architechture of NRPSs and Type I PKSs, 
many cyanobacterial secondary metabolites are, in fact, fusions of NRPs and polyketides. 
In essence, this occurs when Type I PKS modules follow NRPS modules, and vice versa. 
 
2.1.6 Biosynthesis of non-ribosomal peptides in cyanobacteria 
          Over last three decades, a large number of new compounds have been isolated from 
over 4000 strains of marine and freshwater cyanobacteria (Burja et al., 2001). 
Cyanobacterial secondary metabolites posses a wide spectrum of toxicities or biological 
activities and various chemical structures, including nitrogen-containing lipids, novel 
cyclic and linear lipopeptides, fatty acids and other chemicals (Gerwick, et al., 2001; 
Burja et al., 2001; Mayer et al., 2003). Among these secondary metabolites, peptides 
represent a large subclass of bioactive natural products with unique characteristics such 
as non-proteinogenic amino acids, D-amino acids, heterocyclic elements, and 
glycosylated as well as N-methylated residues. Cyanobacteria frequently produce 
peptides by NRPSs or NRPS/PKS (polyketide synthetase) hybrids. The main structure of 
the resulting peptide or hybrid of peptide/polyketide product depends on the number and 
order of modules in NRPS or NRPS/PKS system. 
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           Since the first cyanobacterial NRPS cluster which coded for microcystin 
biosynthesis was cloned and characterized  from Microcystis aeruginosa (Dittmann et al., 
2001), a number of NRPS or hybrid NRPS/PKS gene clusters have been identified and 
sequenced from cyanobacterial genomes (Welker et al., 2006). Only a few NRPS-
containing biosynthetic gene clusters have been characterized from the marine 
cyanobacterium Lyngbya majuscula, including the gene sets of barbamide (Chang et al., 
2002), curacin A (Chang et al., 2004), lyngbyatoxins (Edwards et al., 2004a), 
jamaicamides (Edwards et al., 2004b), hectochlorin (Ramaswamy et al., 2007). No 
biosynthetic gene cluster has been isolated from a freshwater Lyngbya. Indeed only a few 
peptides have been isolated from freshwater Lyngbya. The cyclic peptides, pahayokolides 
A and B are isolated from a freshwater Lyngbya sp. from the Florida Everglades (An et 
al., 2007). Both pahayokolides A and B contain a cyclic undecapeptide and an unusual β-
amino acid, Athmu (3-amino-2,5,7,8-tetrahydroxy-10-methylundecanoic acid). Although 
β-amino acids are common in cyanobacterial peptides, only the pahayokolides, 
lyngbyazothrins A-D and schizotrin A contain Athmu (Zainuddin et al., 2009; Pergament 
et al., 1994). 
           Many microbes are not amenable to cultivation and require time-consuming 
empirical optimization of incubation conditions for mass production of desired secondary 
metabolites for clinical and commercial use (Shuler, 1994). Therefore, a fast, simple 
system for heterologous production of natural products is much desired. In chemical 
synthesis of bioactive cyanobacterial peptides, the use of protecting groups and chiral 
catalysts in regio- and stereoselective reactions is common. Compared with natural NRPS 
or NRPS/PKS strategies, chemical synthesis is difficult to achieve in satisfying yields. 
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NRPSs represent the enzymatic assembly line for the biosynthesis of pharmacologically 
relevant peptides. Understanding the architecture of NRPSs and how they incorporate a 
diverse group of precursors into complex peptides is important, not only for revealing the 
mechanisms of new enzymatic reactions, but also for engineered production of new 
peptides with better therapeutic properties. Recombinate NRPS and NRPS/PKS facilitate 
the sustainable bioproduction of peptides. Herein we report the cloning, partial 
sequencing and characterization of the Pahayokolide A biosynthetic genes of Lyngbya sp. 
strain 15-2. This study provides a better knowledge of these metabolic products and 
underlying biological mechanisms, and ultimately to contribute to the redesigning of 
natural products in order to obtain new bioactive compounds for drug discovery. 
 
2.2 Results and Discussion 
 
2.2.1 The biosynthetic origin of the Athmu moiety in pahayokolides A 
         -Amino acids are not uncommon in cyanobacterial peptides and include Adda (3-
amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid) in microcystins 
(Carmichael, 1994), and nodularin (Annila et al., 1996; Drakenberg, 1996), Ahoa (3-
amino-2,5-dihydroxy-8-phenyloctanoic acid) in nostophycin (Fujii et al., 1999), Ahda (3-
amino-2,5,9-trihydroxy-10-phenyldecanoic acid) in scytonemin A (Helms et al., 1988). 
The biosynthetic precursors and pathway for the Adda moiety of microcystin-LR is the 
only cyanobacterial β-amino acid whose pathway has be elucidated. The Adda moiety of  
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Figure 2 ­ 13. Proposed biosynthesis of Adda 
 
the microcystins has been shown to be of mixed peptide and polyketide origin. Stable 
isotope feeding experiments demonstrated that the biosynthesis of the Adda sidechain 
begins with a phenylalanine starter unit which is extended by four rounds of condensation 
with malonate (Fig. 2-13) (Moore et al., 1991). Thus four PKS (polyketide synthetase) 
modules are involved in the biosynthesis of the polyketide amino acid Adda (Tillett, et al., 
2000). Inspection of the Athmu residue of the pahayokolides suggests a polyketide origin 
as well. We anticipated that the starter unit for the biosynthesis of the Athmu sidechain 
could either be valine (which would require subsequent incorporation of an additional 
seven carbons) or leucine or α-ketoisovalerate, which could be further extended by three 
rounds of condensation with malonate units (Fig. 2-22). We anticipated that the later 
pathway would be more likely than the former. Mehner, et al. (2008), recently proposed a 
similar polyketide pathway for the α-hydroxy-β-amino acids Adha, Aoha and Atpoa. 
         Laboratory cultures of Lyngbya sp. strain were incubated with 13C labeled 
substrates (Fig. 2-14) and harvested. Pahayokolide A was isolated by standard methods 
(Berry et al., 2004). Isolated pahayokolide A was analyzed by 1H and 13C NMR to 
identify sites of 13C incorporation. Assignments of 13C NMR signals and the results of 
isotope incorporation into the Athmu and N-methyl-N-acetyl leucine subunits of 
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pahayokolide A (98) are presented in Table 2-6 and Fig 2-14. These values were 
calculated using the procedure described by Gerwick for barbamide and only the Athmu 
carbons-describe (Williamson, et al., 1999). 
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Table 2 - 6. Isotopic enrichments based on 13C NMR for pahayokolide A 
position δC [1-13C]-Leu [1,2-13C]-Leu [1-13C]-Acetate 
Athmu     
52 172.8, s 0.76 0.51 1.02 
53 72.1, d 0.70 0.95 1.41 
54 48.8, d 0.56 1.36 0.72 
55 35.0, t 0.34 0.39 0.93 
56 69.8, d 0.36 0.72 1.40 
57 36.9, t 0.94 0.58 0.77 
58 71.1, d 2.02 3.98 1.94 
59 72.6, d 0.69 3.29 0.79 
60 41.1, t 1.42 1.03 1.49 
61 24.3, d 1.33 1.22 0.97 
62 23.4, q 1.81 1.76 0.82 
63 21.6, q 1.64 1.59 0.88 
N-Me-Leu     
64 172.4, s 2.26 2.44 2.03 
65 55.4, d 0.35 2.71 1.53 
66 36.8, t 1.5 0.64 1.09 
67 24.8, d 1.32 1.48 0.93 
68 22.9, q 1.25 0.93 0.61 
69 21.2, q 1.19 1.10 0.86 
70 32.8, q 0.71 0.66 0.71 
N-Acyl     
71 174.3, s 0.98 0.73 3.80 
72 21.7, q 1.09 1.35 1.00 
a Significant enrichments are shown in bold. 
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         The 13C NMR spectrum (d-6 DMSO/ D2O) of pahayokolide A (98) derived from [1-
13C] leucine fed cultures showed significant enrichment at C-58 (Fig. 2-15) and C-64 (Fig. 
2-16) while doubly labeled [1, 2-13C] leucine showed enrichment at C-58, C-59, C-64 and 
C-65 as well as the anticipated 13C-13C coupling (Fig. 2-17 and 2-18). Pahayokolide A 
(98) derived from [1-13C] acetate fed cultures showed significant enrichment (nearly 
fourfold) at C-71 and more modest enrichment at C-58 and C-64 (Fig. 2-19 and 2-20). 
The experiment reported here demonstrated that our original NMR assignments of C-71 
and C-47, C-31 and C-64 were switched. The corrected assignments are C-71, 174.3 ppm; 
C-47, 173.3 ppm; C-31, 172.6 ppm; C-64, 172.4 ppm. The incorporation of [1-13C] 
acetate at C-58 and C-64 occurs via the condensation of acetate with α-ketoisovalerate 
during the biosynthesis of leucine from valine (Fig. 2-21). 
         No enrichment of C-52 through C-57 was observed by feeding Lyngbya sp. Strain 
15-2 with [1-13C] acetate indicating that the Athmu moiety is not directly derived from 
acetate. The results of our [1-13C] acetate feeding experiments are not consistent with our 
original hypothesis that the Athmu moiety is derived from three units of acetate via 
condensation by a polyketide synthetase. The failure to observe incorporation of [1-13C] 
acetate at C-52, C-54 and C-56 was surprising; however enrichment at C-71, C-58, and 
C-64 serves as an internal control indicating that the [1-13C] acetate feeding experiment 
was successful. Clearly the Athmu moiety is not constructed directly from acetate (Fig. 2-
22). Alternatively, we suggest that these α-hydroxy-β-amino acids may arise from 
incorporation of an amino sugar such as kanosamine, ezoaminuroic acid and desosamine 
(Fig. 2-23). Amino sugars are part of the peptidoglycan cell wall of gram negative  
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Figure  2  ­  18 Natural abundance (top) and [1,2-13C]-L-leucine labeled (bottom) 13C NMR of 
pahayokolides A (98) (170~175 ppm) 
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 Figure 2 ­ 19. Natural abundance (top) and [1-13C]-acetate labeled (bottom) 13C NMR of 
pahayokolides A (98) (165~180 ppm) 
 
Natural abandance 13C NMR of pahayokolide
[1-13C]-acetate labeled 13C NMR of pahayokolide
 
Figure 2 ­ 20. Natural abundance (top) and [1-13C]-acetate labeled (bottom) 13C NMR of 
pahayokolides A (98) (55~75 ppm) 
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Figure 2 ­ 21. Biosynthesis of L-leucine from valine 
 
OH OH
OH
OH
ONH2
OHOH
O
NH2
ONa
O
HO SCoA
O O
Leucine
Sodium acetate
3 Malonyl-SCoA
Athmu
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bacteria including cyanobacteria. Feeding of [1-13C] glucose to Lyngbya sp. failed to 
yield C-52 labeled pahayokolide A. However, it is possible that glucose is too far 
upstream of the Athmu precursor to show enrichment. 
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kanosamine                                          ezoaminuroic acid                              desosamine 
 
Figure 2 ­ 23. Structure of three amino sugars 
 
2.2.2 Identification putative peptide and polyketide synthetases in Lyngbya sp. strain 
15-2 
         The presence of non-proteinogenic amino acids, including D-homophenylalanine, 
D-glutamine, Dhb and Athmu in the structure of pahayokolides A indicated that NRPSs 
were involved in the biosynthesis of pahayokolide A. Our feeding experiment indicated 
the Athmu moiety does not arise directly from intact acetate units assembled by PKSs. It 
is very possible that a PKS is not involved in the biosynthesis of pahayokolide A. To 
identify the NRPS and questioned PKS genes in Lyngbya sp. strain 15-2, degenerate PCR 
primers targeted to conserved sequence motifs of known NRPS and PKS genes were used 
with chromosomal DNA of Lyngbya sp. strain 15-2. The use of degenerate primers 
targeting the A3 and A8 core motifs of NRPSs and the β-ketosynthase (KS) domain of 
PKSs resulted in products of the expected size (1 kb and 0.7 kb, respectively) (Fig. 2-24). 
The 1 kb and 0.7 kb gene fragments amplified from Lyngbya sp. strain 15-2 were 
98 
 
subcloned in pCR 2.1 TOPO TA (Invitrogen) and sequenced. The resulting sequences 
were searched against NCBI’s nonredundant database by using the BLASTX or BLASTP 
algorithms (Altschul et al., 1997). 
 
0.5 kb
1.0 kb
3.0 kb
 M  B   C   L  M    C       B       L
700 bp
1 kb
500 bp
 
Figure 2 ­ 24. PCR of genomic DNA from Lyngbya sp. Strain 15-2 using degenerate NRPS and PKS 
primers. 
 M, marker; B, blank control; C, positive control; L, Lyngbya DNA. 
 
         One of the 20 NRPS clones analyzed (pLN2) showed high homology to the 
phenylalanine-activating domain from ociB belonging to the NRPS complex responsible 
for oscillapeptin E production (gb|ABI26078.1|; 47% identity, 139 of 293 aligned amino 
acids) in Planktothrix agardhii NIVA-CYA 11. One of the 20 NRPS clones (pLN6) 
showed significant homology to a threonine-activating module from mcnB belonging to 
the NRPS complex responsible for cyanopeptolin production (gb|AAZ03551.1|; 74% 
identity, 228 of 307 aligned amino acids) in Microcystis sp. NIVA-CYA 172/5. One of 
the 20 NRPS clones (pLN8) showed significant homology to a serine-activating module 
from NosA encoded by a gene belonging to the NRPS complex responsible for 
nostopeplide A production (gb|AAF15891.2|AF204805_1; 73% identity, 210 of 287 
aligned amino acids) in Nostoc sp. GSV224. The deduced amino acid sequences of pLN2, 
99 
 
pLN6 and pLN8 were used to predict their substrate specificities by the method of 
Stachelhaus et al. (1999) and Challis et al. (2000). The primary sequences of the 
phenylalanine-activating A domain of gramicidin S and the translated sequences of pLN2, 
pLN6 and pLN8 were aligned by using Jotun-Hein method (Hein, 1994), and the 
signature amino acids conferring substrate recognition were compared to a database of 
known NRPS A domains (http://www-ab.informatik.unituebingen.de/toolbox/index.php? 
view=domainpred). The substrate specificities of pLN2, pLN6 and pLN8 were predicted  
 
Table 2 ­ 7. Activated substrates and the binding pocket amino acid residues of A domains in 
pLN2, pLN6 and pLN8 
Binding pocket of A domain  
235 236 239 278 299 301 322 330 
Proposed 
substrates 
pLN2 D A F V L A A V Phe 
pLN6 D F W N I G M V Thr 
pLN8 D V W H I S L I Ser 
 
to activate the amino acid substrates phenylalanine (pLY2), threonine (pLY6), and serine 
(pLY2) (Table 2-7). Phenylalanine, threonine, and serine are present in the structure of 
pahayokolide A. Sequence analysis of the 20 PKS clones (pLP1-20) indicated that all the 
PKS PCR products contained a single, identical KS domain and showed high homology 
to the KS domain from BarE belonging to the PKS complex responsible for barbamide 
production (gb|AAN32979.1|; 72% identity, 181 of 251aligned amino acids) in Lyngbya 
majuscule. The conserved active site motif (GPSVNVQTACSTSLVTVH) and catalytic 
cysteine residue for the KS domain were observed. The result conflicted with the logic 
rule that the long side chain of Athmu was assembled by three rounds of ketide 
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extensions if PKSs were involved. Therefore, it is not unreasonable to assume that Athmu 
may arise from the incorporation of a larger single unit, such as an amino sugar, rather 
than acetate units by PKSs. 
 
Table 2 ­ 8. Partial sequencing of Fos11, 45, 22, 83 
Fosmid and modules Proposed domains Binding pocket of A 
domain 
Proposed substrates 
Fos11 C   APhe   PCP DAFVLAAV phenylalanine 
 C   APhe/Leu   PCP DAWLLGAV Phenylalanine/leucine 
 C A? PCP DAFVLSSF No prediction 
    
Fos45 C   APhe/Leu   PCP DAWLLGAV Phenylalanine/leucine 
    
Fos22 C   APhe/Leu   PCP DAWLLGAV Phenylalanine/leucine 
    
Fos83 C   APhe/Leu   PCP DAWLLGAV Phenylalanine/leucine 
 
2.2.3 Cloning and partial characterization of the NRPS genes for pahayokolide A 
production in Lyngbya sp. strain 15-2 
         Chemical analysis of Lyngbya sp. Strain 15-2 has yielded only pahayokolide A, its 
cyclic fragment (pahayokolides B), and its conformers (pahayokolides C-D), as major 
metabolites (An et al., 2007). However, it remained possible that additional NRPS 
biosynthetic pathways are present in the genome whose products have yet to be 
characterized. Therefore, a strategy was devised to probe Lyngbya sp. strain 15-2 broadly 
for fosmids containing phenylalanine specific A domains of NRPS, and then focus on 
specific structural characteristics to identify the pathway of interest. 
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         The fosmid library was constructed following the manufacture’s protocol 
(Epicentre). About 12,760 colonies (60-fold coverage of the genome) were screened by 
colony PCR using the specific NRPS primers (Babcock et al., 2007). Four fosmids 
(Fos11, Fos45, Fos22, and Fos83) were sequenced partially and yielded three NRPS 
module products (Table 2-8). Fos11, the largest fosmid containing all the three NRPS 
modules, was chosen for full sequencing (Fig. 2-25). 
 
1 kb
2 kb
3 kb
5 kb
M  11   45   22   83
 
 
Figure 2 - 25. NotI and Bsu36I restriction map of four 
NRPS-positive fosmids of Lyngbya sp. strain 15-2.  
M, maker; 11, Fos11; 45, Fos45; 22, Fos22; 83, Fos83.  
 
         A contiguous 45 kb region was partially sequenced (37 kb) to reveal 14 putative 
opening reading frames (ORFs). The cluster was predicted to encode a NRPS assembly 
line responsible for biosynthesis, transport and degradation of a peptide in Lyngbya sp. 
strain 15-2. The 14 ORFs were transcribed in the same direction except ORF2, and 
showed a high degree of similarity to a number of bacterial NRPSs or associated proteins. 
Part of the Pah biosynthetase, including PahA, PahB, PahC and PahI, was analyzed in 
detail. As shown in Table 2-9, PahA is a monomodular NRPS harboring the first module 
and a C domain with the domain structure of A-PCP-C. The first module starts with an A 
domain, which suggested that it might be the initial module and activate one amino acid. 
PahB consisted of A-PCP-C-A-PCP, which was assumed to activate two amino acids. 
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The C domain of PahA became a module with the first two domains (A-PCP) of PahB. 
PahI was composed of three modules with the domain structure of (C-A-PCP)2-C-A-
PCP-Te, which might be responsible for activating three amino acids, and releasing 
mature peptide during peptide biosynthesis. A fragment of 8 kb between PahC and PahI 
remained unsequenced.  
 
Table 2 ­ 9. Deduced functions of encoded proteins in the pah gene cluster of Lyngbya sp. 
strain 15­2 
substrate Protein Length 
(aa) 
Proposed 
functions 
Sequence similarity I/S Binding pocket 
of A domain Proposed 
& identity 
product 
PahA 1019 A  PCP  C Glu racemase [Bacillus 
thuringiensis serovar 
huazhongensis  
BGSC 4BD1] 
37%, 
58% 
DTWTVGAIEK Arg 
70% 
D-Gln 
PahB 1572       
PahB1  A  PCP NcpA [Nostoc sp. 
ATCC53789] 
45%, 
64% 
DACXLAAVCK Tyr 
70% 
Pro 
PahB2  C  A  PCP Phe module of SubC 
[Bacillus subtilis] 
47%, 
64% 
DAFVLAAVCK Phe 
80% 
Phe 
PahC        
PahC1  C  A  PCP D-Phe module of BacC 
[Bacillus licheniformis] 
47%, 
64% 
DAWVLAACK Phe 
80% 
Gly 
PahC2  C ?      
PahI        
PahI-4  ?  A  PCP   ????AVCK   
PahI-3   C  A  PCP D-Phe module of BacC 
[Bacillus licheniformis] 
49%, 
67% 
DAWVLAAVCK Phe 
80% 
D-
Homophe 
PahI-2  C  A  PCP NosD [Nostoc sp. GSV224] 38%, 
56% 
DAXVLAAVCK Tyr 
70% 
Pro 
PahI-1  C  A  PCP  TE Phe module of SubC 
[Bacillus subtilis] 
47%, 
64% 
DATKYGAVNK Asp 
80% 
Athmu 
 aa, amino acid; I, identitity; S, similarity. 
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         In order to elucidate predicted substrates of A domains in PahA, PahB, and PahC 
PahI, primary sequences between core motifs A3 and A10 of A domains were aligned to 
corresponding sequence of PheA, and substrates of the binding-pockets were determined 
by their proximity to conserved sequences (Conti, et al., 1997; Stachelhaus, et al., 1999). 
As shown in Table 2-9 and Fig. 2-26, on the basis of known nonribosomal specificity-
conferring code (Stachelhaus, et al., 1999), the specified substrates of the A domain in 
PahA were deduced to be Arg which was different from the glutamine in pahayokolide A. 
The binding pocket of A domains of glutamine and arginine should be similar because 
their hydrophobicity is close. The specificity of A domains of PahB-1 and PahI-2 was the 
tyrosine residue, which was discordant with the corresponding amino acid proline in the 
product respectively. The discoordance can also be explained by their close 
hydrophobicity (Tyr, 1.3; Pro, -1.6). The specified substrate of the A domain of PahB-2 
and PahI-3 was consistent with corresponding amino acid in the product. Most of the 
bacterial NRPS gene clusters are organized in a linear order that parallels the order of the 
amino acids in the resultant peptides. In spection of the pah gene cluster (Table 2-9) 
showed that the Pah modules were not organized according to the collinear rule for 
pahayokolide biosynthesis. One structural variation that deviated fron the collinear rule in 
the pah gene cluster was that PahC-1 functioned before PahB-1. PahC-1 was supposed to 
activate glycine, but its specificity was phenylalanine. However, the binding-pockets of 
available A domains activating glycine showed weak homology (Challis et al., 2000). 
The predicted specificity of PahI-1 disagreed with the corresponding amino acid (Athmu) 
in pahayokolide A. The inharmony is reasonable because the database of nonribosomal 
specificity-conferring code does not include Athmu. The lack of PKS domains in PahI-1 
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further proved our former suggestion that Athmu is not assembled by PKSs and may arise 
from incorporation of an amino sugar such as dsosamine or ezoaminuroic acid. The high 
homology of PahA and PahI-3 with D-amino acid activating domain were line with the 
corresponding D-glutamine and D-homophenylalanine in pahayokolide A.  
 
 
Figure 2 ­ 26 A predicted model for the biosynthesis of pahayokolide A templated by the Pah 
synthetase 
 
         A type I TE domain was integrated into PahI, the final modules of the assembly line 
complex. The TE domain showed high homology with TE domains of BarG 
(gb|AAN32981.1|; Identity 33%, 95 of 287 aligned amino acids) in Lyngbya majuscule 
and CrpD (gb|ABM21572.1|; Identity 33%, 88 of 275 aligned amino acids) in Nostoc sp. 
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ATCC 53789. The three conserved residues in the catalytic triad, serine84, aspirate111 
and histine201 were observed. The conserved proline29 was crucial for driving the mode 
of catalysis to cyclization instead of hydrolysis, and preferred producing cyclic products. 
It is consistent with the structure of pahayokolides. As the proline residue can shield the 
hydroxyl group of serine84 and affects the characteristics of the oxyanion hole. A glycine 
at this position will prefer a nucleophilic attack of a water molecule on the acyl-enzyme 
intermediate and form a linear product (Bruner et al., 2002).  
         Usually one typical NRPS modules spans across about 3 kb. A 8 kb DNA fragment 
can only bear three NRPS modules. On the basis of the pahayokolide A structure and the 
deduced functions of the individual NRPS modules, the unsequnced fragment of 8 kb 
between PahC and PahI was predicted to encode four or five NRPS modules. These 
NRPS modules were proposed to assembly one N-acetyl-N-methyl-L-leucine, one 
threonine, one serine, and two Dhb residues into pahayokolide A. The module activating 
N-acetyl-N-methyl-L-leucine does not need to be in the 8 kb. Dhb arises from the 
dehydration of threonine. Only three NRPS modules are needed if one of these three 
NRPS modules activate two or three threonine iteratively. Therefore, the 8 kb of 
unsequenced DNA fragment is repetitive and offers a challenge for sequencing.  
         Antibiotic production genes have been found nearly in all cases to be clustered in 
one region of the bacterial chromosome, consisting of structural, resistance, and 
regulatory genes. The pah cluster also contains 10 ORFs that may be involved in 
pahayokolides resistance, transport and degradation (Table 2-10). The 2436-bp ORF10, 
which is located 42 bp downstream and transcribed in the same direction of pahI, 
encodes a putative 92.9-kDa protein with high homology to TonB-dependent receptor 
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plug. TonB-dependent outer membrane proteins take up molecules that are too large to 
pass through porins, using energy provided by the membrane-spanning protein TonB. 
Many siderophores are peptidic molecules that are synthesized by NRPS systems in 
Gram negative bacteria. Siderophores bind iron extracellularly, and then are taken up by  
 
Table 2 ­ 10. Deduced functions of the opening frame reading frames in the pah gene cluster 
Protein Amino 
acids 
Proposed function Sequence similarity Identity/ 
Similarity 
ORF1 410 hypothetical protein 
ALPR1_04198 
 
Algoriphagus sp. PR1 35%, 53% 
ORF2 282 α/β hydrolase family 
protein 
 
Algoriphagus sp. PR1 66%, 82% 
ORF3 401 penicillin-binding protein, 
β-lactamase class C 
 
Spirosoma linguale DSM 74 40%, 56% 
ORF4 369 efflux transporter, RND 
family, MFP subunit  
 
Microscilla marina  
ATCC 23134 
29%, 52% 
ORF5 418 lipoprotein releasing 
system, permease 
component 
 
Algoriphagus sp. PR1 78%, 90% 
ORF6 226 ABC-type antimicrobial 
peptide transport system, 
ATPase component  
 
Spirosoma linguale DSM 74 
 
62%, 82% 
ORF7 737 Signal Transduction 
Histidine Kinase  
 
Algoriphagus sp. PR1 45%, 63% 
ORF8 165 response regulator 
 
Algoriphagus sp. PR1 67%, 84% 
ORF9 183 two-component system 
response regulator protein 
 
Pedobacter sp. BAL39 34%, 60% 
ORF10 812 TonB-dependent receptor 
plug 
Dyadobacter fermentans DSM 
18053 
36%, 57% 
 
the cell through a TonB-dependent membrane transport system (Faraldo-Gomez et al., 
2003). The 675-bp ORF6, which is located 5713 bp upstream and transcribed in the same 
direction of pahA, encodes a putative 25.7-kDa protein with high homology to ATP 
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banding cassette (ABC) transporters. It suggested that ORF6 may be involved in 
exporting pahayokolides from the cyanobacterium. Located 9382 bp downstream from 
pahA is ORF3 (1203 bp) with high homology to β-lactamases. The peptidase ORF3 may 
be involved in the hydrolysis of the peptide. It is supported by evidence that homologous 
MlrB (51%/31% similarity/identity) is involved in microcystin degradation in the 
bacterium Sphingomonas linguale DSM74. 
 
2.3 Materials and Methods 
 
2.3.1 Culture conditions of Lyngbya sp. strain 15-2 
         Lyngbya sp. strain 15-2 collected from the Florida Everglades was cultured in BG11 
medium supplemented with 0.19 M Na2CO3 buffered with 2-morpholinoethanesulfonic 
acid (MES) at pH 7.2 at 20~22 C under continuous white light. After one month 
Lyngbya sp. strain 15-2 was fed with 13C labeled substrates (50mg/tray each time) for 
three times on the first, fourth, and sixth days. Samples of biomass were harvested on the 
eighth day, dried with paper towels to remove medium, stored at -80 C in an ultracold 
frezer. 
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2.3.2 Stable isotope incorporation experiments 
         Samples of biomass were harvested from cultures of Lyngbya sp. strain 15−2 and 
lyophilized. The freeze-dried biomass was pulverized in liquid nitrogen, and extracted in 
70% MeOH (in water) at room temperature for two days. Following solvent removal, 
water-soluble constituents were separated by RP C18 solid-phase extraction using a 
stepwise gradient solvent system from 20% MeOH in water to 100% MeOH (Berry et al., 
2004). The bioactive 80% and 100% MeOH fractions were then separately 
chromatographed on prep-HPLC (Alltech Alltima C18, 10 m, 250  22 mm) using 75% 
MeOH in H2O and monitored at 220 nm. Pahayokolides A-D were obtained. The purity 
of pahayokolides was checked by analytical HPLC (Alltech Apollo C18, 5 m, 250 mm  
4.6 mm) using 70% MeOH in H2O and monitored at 220 and 254 nm.  
 
2.3.3 NMR experiment 
         NMR spectroscopic data were acquired in DMSO-d6-D2O (3:7) on a Bruker 400 or 
600 MHz AVANCE spectrometers. The NMR data were processed with Topspin/XWIN-
NMR, and analyzed using Sparky software (An et al., 2007). 
 
2.3.4 DNA manipulations 
         High molecular weight (HMW) genomic DNA for the construction of Lyngbya sp. 
strain 15-2 genomic library was prepared from flash frozen, pulverized filaments of 
Lyngbya sp. strain 15-2 using thr combination method of phenol/chloroform extraction 
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and Genomic DNA Purification Kit (Qiagen). DNA from Lyngbya sp. strain 15-2 for 
PCR amplification was obtained using FastDNA SPIN for Soil Kit (Bio 101 Systems). 
For PCR amplification of A domains of NRPSs and KS domain of PKSs, degenerate 
primers were used (Table 2-11). Plasmid preparation was carried out by using 
commercial kits (Qiagen).  
 
Table 2 ­ 11. primer sequences 
primer Comments Sequence (5’ to 3’) 
NRPS2upper Degenerate NRPS forward GCN GCN GGN GCI TAY GTI CC 
NRPS2lower Degenerate NRPS reverse CCN CKD ATY TTN ACY TG 
KS4U Degenerate PKS forward MGI GAR GCI YTI CAR ATG GAY CCI 
CAR CAR MG 
KS5L Degenerate PKS reverse GGR TCN CCI ARY TGI GTI CCI GTI CCR 
TGI GC 
PheLN02f Phenylalanine specific NRPS forward TCA AAC CCC GTA CCT CAA AG  
PheLN02r Phenylalanine specific NRPS reverse CCG ATG GTG ATT TGG CTA GT 
ThrLN06f Threonine specific NRPS forward ACC CAA CCT ATC CCC AAG AC 
ThrLN06r Threonine specific NRPS reverse TAA ATC GCC TTC TGT TTC GG 
SerLN08f Sernine specific NRPS forward CGA ACA TAA CGC CCA AAT CT 
SerLN08r Sernine specific NRPS reverse GAA GGC ACA AAA TGC AAG GT 
 
2.3.5 Construction of the fosmid library 
         The Lyngbya sp. strain 15-2 fosmid library was constructed using the CopyControl 
Fosmid library production Kit (Epicentre) following the manufacturer’s protocol. The 
only exception was that the HWM genomic DNA was not sheared before being end- 
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repaired. About 12760 colonies (~ 60-fold coverage of the genome) were obtained. The 
average size of insert DNA was 40 kb.  
 
2.3.6 Screening of the fosmid library 
         The fosmid library was split into 12 pools (Lyn FG1 to Lyn FG12) and screened by 
PCR with NRPS specific primers. Among the six NRPS positive pools, Lyn FG1 were 
subdivided further into 10 subpools and screened by PCR with NRPS and specific 
primers (Figure 2-27). Ninety-six single colonies were picked up from each NRPS 
 
split into 12 pools and screen using
plasmid NRPS PCRs
Lyn FG2, FG3 FG7, FG11,
FG12 waiting for test
Lyn FG1G7 to 
FG1G10 waitimg 
for testingSplit into 8 pools and 
screen using plasmid 
NRPS PCRs
Split into 8 pools and 
screen using plasmid 
NRPS PCRs
Split into 8 pools and 
screen using plasmid 
NRPS PCRs
Split into 8 pools and 
screen using plasmid 
NRPS PCRs
Lyn FG1G3 Lyn FG1G5 Lyn FG1G6Lyn FG1G4
96 single colonies,
Colony NRPS PCR
Lyn FG1G3G4#11, #45
Lyn FG1G3G6#22
split into 10 subpools 
and screen using plasmid 
NRPS PCRs
Lyn FG1
Lyn FG1G3G3
Lyn FG1G3G4
Lyn FG1G3G6
Lyn FG1G3G7
Lyn FG1G3G8
Lyn FG1G4G2
Lyn FG1G4G3
Lyn FG1G4G4
Lyn FG1G4G6
Lyn FG1G4G7
Lyn FG1G4G8
Lyn FG1G5G3
Lyn FG1G5G4
Lyn FG1G5G7
Lyn FG1G5G8
Lyn FG1G6G5
Lyn FG1G6G6
Lyn FG1G6G7
Lyn FG1G5G8#83
96 single colonies,
Colony NRPS PCR
Genomic library of Lyngbya sp. strain 15-2
   
Figure 2 ­ 27. Screening of the genomic library of Lyngbya sp. strain 15-2 
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positive subgroup of Lyn FG1G1 to Lyn FG1G6. Each group of 96 single colonies was 
cultured and combined across 8 rows and down 12 columns. Colony PCR was then 
performed on the 20 pools of cells with NRPS specific primers (Fig. 2-28). Finally, four 
NRPS positive fosmids (Lyn FG1G3G4#11, #45, Lyn FG1G3G6#22 and Lyn 
FG1G5G8#83) were sent to Eurofins MWG Operon for DNA sequencing. 
 
C1     C2     C3     C4     C5     C6      C7     C8    C9     C10    C11   C12
A1
A2
A3
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A7
A8  
C1     C2     C3     C4     C5     C6      C7     C8    C9     C10    C11   C12
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A5
A6
A7
A8  
Figure 2 ­ 28. Preparation of 20 pools of cells for the genomic library screening.  
Left, 12 pools from combining across 8 rows; right, 8 pools from combining down 12 columns 
 
2.3.7 Sequence analysis 
         Database searches for genes and proteins for sequence homology with the putative 
NRPS and PKS were performed by using the NCBI (National Center for Biology 
Information) BLAST service. 
 
2.4 Conclusions 
 
         The biosynthesis of the Athmu sidechain arises from leucine or α-ketoisovalerate. 
112 
 
Our prediction that this subunit is further extended by three rounds of condensation with 
acetate was based on the biosynthetic pathway for the Adda sidechain of microcystin-LR. 
However, stable isotope incorporation experiments using both [1-13C] acetate and [1,2-
13C] acetate demonstrated that this was not correct. Incorporation of the acetate label at 
other positions which may be predicted from primary metabolic pathways serves as an 
internal control experiment, and validates the lack of incorporation into the Athmu 
moiety. 
         Putative peptide and polyketide synthetases in Lyngbya sp. strain 15-2 were 
identified by using a PCR method and degenerate primers derived from conserved core 
sequences of known NRPSs and PKSs. The subcloned NRPS fragments (pLY) obtained 
by degenerate PCR showed a high level of homology to the phenylalanine (pLY2), 
threonine (pLY6) and serine-activating (pLY8) A domains. Substrate-binding pocket 
analysis suggested that the deduced A domains of pLY2, pLY6 and pLY8 indeed 
activates phenylalanine, threonine and serine, respectively. All the subcloned PKS 
fragments (pLP) obtained by degenerate PCR showed a high level of homology to the KS 
domain from BarE. Identification of one unique KS domain conflicted with the logic rule 
that the long side chain of Athmu was assembled by three rounds of ketide extensions if 
PKSs were involved. However, it does not rule out the possibility of incorporation of an 
unusual subunit through a Claisen type condensation similar to that used for the 
construction of polyketides.  
         The genomic library of Lyngbya sp. strain 15-2 was constructed and screened by 
colony PCR. Partial sequence showed that the genetic architecture of the pah biosynthetic 
system is comprised of thirteen genes in two transcriptional units. Besides ten genes 
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responsible for peptide resistance, transport and degradation, six NRPS modules were 
identified. Although the predicted substrate specificities of NRPS did not agree with the 
structure of pahayokolide A, the disagreement could be explained. However, no PKS 
gene was found in the pah gene cluster.  
 
Significance and Future Work 
 
         Lyngbya continues to be a source of novel natural products, many of which are 
bioactive. Pahayokolide A represents a bioactive branched-cyclic polypeptide possessing 
a usual β-amino acid and D-amino acids. Pahayokolide A shows a spectrum of biological 
activities consistent with their function as a defense metabolite, including cytotoxicity, 
ichthyotoxicity and antimicrobial activity. This study was successful in determining the 
absolute configuration of pahayokolides A-D using the advance Marfey’s method and 
figuring out the biosynthetic origin of the Athmu moiety using a classic precursor feeding 
and NMR detection approach. Great insight was achieved by identifying putative peptide 
and polyketide synthetases in Lyngbya sp. strain 15-2 using PCR. Based on the structural 
features of pahayokolide A and biosynthetic finding, a set of gene probes was 
constructed, which led to the efficient identification of a fosmid containing portion of the 
pahayokolide A gene cluster from a total genomic library. Sequencing of the fosmid and 
assembly of the pathway revealed the pah genes encoding the enzymes catalyzing the 
biosynthesis of pahayokolide A. The future studies are required to complete the 
sequencing of 8 kb repetitive fragment in Fosmid11. To determine whether the clone 
peptide synthetase gene pah is required for pahayokolide synthesis, gene disruption of 
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pah in the genome of Lyngbya sp. strain 15-2 should be performed by homologous 
recombination. However, nobody has done homologous recombination in a Lyngbya, 
which must wait for the development of the appropriate molecular bilogical methods. 
This report broadens new peptide synthetases waiting for discovery from Lyngbya 
species. One potential application of Lyngbya NRPS is to use particular domains and 
enzymes for combinatorial biochemistry. This facilitate future attempt to produce novel 
bioactive peptides with improved therapeutic efficacy and lower toxicity.  
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